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Summary 
Acute hypoxia impairs aerobic exercise by reducing the capacity for maximal O2 uptake 
(VO2max). This is mainly the consequence of a lower arterial O2 content (caO2) and, in severe 
hypoxia, cardiac output during maximal exercise as the combination of these two factors 
attenuates convective O2 supply to the exercising muscle cells. Nevertheless, the 
incapacitating effect of hypoxia is partially restored during prolonged exposure as an 
increased renal erythropoietin release induces polycythemia that normalizes caO2. Since this 
mechanism may benefit performance not only in hypoxia but also in normoxia different forms 
of altitude training were developed all aiming to enhance athletic performance at sea level. 
 
The purpose of the present project was to enhance our understanding regarding the interaction 
between both, acute and chronic hypoxia and aerobic exercise. In acute hypoxia the 
contribution of the intrinsic responses of the pulmonary and the cerebral circulation to the 
reduction in VO2max was investigated. Specifically, we hypothesized that the hypoxia-
induced rise in pulmonary artery pressure induces exercise limitations by increasing right 
ventricular afterload and/ or promoting pulmonary ventilation-perfusion mismatch. 
Furthermore, we suggested that the cerebral hypoxia that develops during exercise at altitude 
would limit VO2max by accelerating the development of supraspinal fatigue. Regarding 
chronic hypoxia we tested the efficacy and underlying mechanisms of the contemporary 
altitude training strategy, i.e. the Live High – Train Low approach, on elite endurance athletes 
in a double-blinded and placebo-controlled study design. 
 
The results collected in three independent studies revealed the following: 
1) At 4,559 m altitude pulmonary vasodilation induced by the glucocorticoid 
Dexamethasone elevates VO2max of individuals present with an excessive 
vasoconstrictive response to hypoxia without affecting arterial O2 saturation (SaO2). A 
direct comparison to normal individuals further suggested a larger hypoxia-induced 
exercise impairment in these individuals but also no differences in SaO2 during maximal 
exercise. We thus conclude that hypoxic pulmonary vasoconstriction may contribute to 
the reduced VO2max in acute hypoxia potentially by increasing right ventricular afterload 
and thereby attenuating cardiac output. 
2) Although administration of CO2 during exercise at 3,454 m altitude elevated cerebral 
blood flow and, as a consequence, cerebral oxygenation, VO2max remained unaffected. 
This indicates that the contribution of the reduced cerebral oxygenation on the limitation 
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of VO2max in hypoxia is neglectable. Nevertheless, as a VO2max test induces 
progressive demand for muscular O2 supply, the capacity of the O2 transport system 
might have been exhausted before supraspinal fatigue occurred, and thus we cannot 
exclude that the decline in cerebral oxygenation may play a role during submaximal 
exercise in hypoxia. 
3) Four weeks of discontinuous (16 hours per day) exposure to normobaric hypoxia 
corresponding to 3,000 m combined with daily training in normoxia failed to benefit the 
performance of elite endurance athletes. This was explained by the absence of an effect of 
hypoxia on total red cell volume. These findings suggest a potential role of a placebo-
effect in earlier studies and indicate that four weeks of discontinuous hypoxic exposure 
may be insufficient to induce physiological adaptations. Athletes should take this into 
consideration before shouldering the inconveniences associated with Live High – Train 
Low altitude training. 
 
In brief, the present results support a limiting role of pulmonary vasoconstriction but not of 
attenuated cerebral oxygenation on VO2max in hypoxia. They further indicate that altitude 
training following the Live High – Train Low strategy may not be superior to conventional 
endurance training. 
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Zusammenfassung 
Akute Hypoxie führt zu einer Reduktion der maximalen O2 Aufnahmekapazität (VO2max) 
und beeinträchtigt dadurch die aerobe Leistungsfähigkeit. Die Hauptursache für die Abnahme 
von VO2max ist ein verringerter O2 Transport zu der arbeitenden Muskulatur, der durch einen 
tieferen arteriellen O2-Gehalt (caO2) und in schwerer Hypoxie zusätzlich durch ein 
vermindertes maximales Herz-Minuten-Volumen zustande kommt. 
Bei chronischer Hypoxie-Exposition führt jedoch eine verstärkte renale Erythropoietin-
Ausschüttung zu einer Erhöhung der Hämoglobinkonzentraion im Blut. Dadurch normalisiert 
sich caO2 allmählich, wodurch sich auch die aerobe Leistungsfähigkeit teilweise erholt. Da 
eine solche Anpassung des Blutes allerdings nicht nur die Leistungsfähigkeit in Hypoxie, 
sondern auch die in Normoxie verbessern könnte, erhoffen sich viele Athleten einen 
Wettkampfvorteil aus dem Akklimatisationsprozess. Dazu wurden verschiedene Formen von 
Höhentraining entwickelt, die alle eine Verbesserung der Leistungsfähigkeit in Normoxie 
anstreben. 
 
Das Ziel dieses Projekts war es, die Auswirkungen von akuter und chronischer Hypoxie auf 
die aerobe Leistungsfähigkeit zu untersuchen. In akuter Hypoxie wurde getestet, ob die 
spezifischen Reaktionen von Lungen- und Hirnkreislauf zu der Verminderung von VO2max 
beitragen. Wir vermuteten, dass die pulmonale Vasokonstriktion in Hypoxie VO2max 
beinträchtigt, indem sie die rechtsventrikuläre Nachlast erhöht und ein optimiertes 
Ventilations/ Perfusions-Verhältnis verhindert. Weiterhin spekulierten wir, dass die 
verminderte O2 Versorgung des Gehirns die Entstehung von supraspinaler Ermüdung 
beschleunigt und dadurch eine raschere Erschöpfung erzwingt. 
Hinsichtlich chronischer Hypoxie untersuchten wir die Wirkung der vielverspechendsten 
Höhentrainingsstrategie (Hoch leben – Tief trainieren) auf die Leistungsfähigkeit von 
hochtrainierten Ausdauerathleten, sowie die Mechanismen, die einer eventuellen 
Verbesserung unterliegen. 
 
Die folgenen Ergebnisse stammen aus drei unabhängigen Studien: 
1) Bei Probanden, die in akuter Hypoxie zu exzessiver pulmonaler Vasokonstriktion neigen, 
verbesserte eine durch das Glukokortikoid Dexamethason bewirkte pulmonale 
Vasodilatation VO2max auf einer Höhe von 4„559 m.ü.M. Dies geschah ohne eine 
Erhöhung der arteriellen O2-Sättigung (SaO2) bei maximaler Belastung. Weiterhin 
tendierten diese Probanden im direkten Vergleich zu einer Kontrollgruppe zu einer 
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stärkeren Verringerung von VO2max in Hypoxie, wobei auch hier keine Unterschiede in 
SaO2 bei maximaler Belastung vorlagen. Aus diesen Ergebnissen schliessen wir, dass die 
pulmonale Vasokonstriktion in akuter Hypoxie zur Verringerung von VO2max beiträgt. 
Die Ursache könnte eine gesteigerte rechtsventrikuläre Nachlast sein, die das Herz-
Minuten-Volumen reduziert. 
2) Auf 3„454 m.ü.M. erhöhte eine inspiratorische Administration von CO2 die arterielle 
Blutversorgung und damit die Oxygenierung des Gerhirns. Entgegen unserer Hypothese 
hatte diese jedoch keinen Effekt auf VO2max. Dies zeigt, dass die Abnahme der 
cerebralen Oxygenierung bei der Verringerung von VO2max in Hypoxie keine 
entscheidende Rolle spielt. Allerdings könnte die zunehmende Belastung während der 
VO2max Tests und der damit verbundene ansteigende O2 Bedarf in den Skelettmuskeln 
die Kapazität des O2 Transportsystems überfordert haben, bevor bevor die cerebrale 
Hypoxie zu supraspinaler Ermüdung führte. Daher kann nicht ausgeschlossen werden, 
dass die verminderte cerebrale Oxygenierung in Hypoxie die Leistungsfähigkeit in 
submaximalen Tests beeinflussen könnte. 
3) Vier Wochen diskontinuierliche normobare Hypoxie-Exposition (16 Stunden/ Tag, 
entsprechend 3„000 m.ü.M.) bewirkten keine Erhöhung des Gesamtvolumens der 
Erythrozyten von hochtrainierten Ausdauerathleten und führte daher zu keiner 
Leistungsverbesserung. Dies lässt vermuten, dass Athleten in früheren Studien von einem 
Placebo-Effekt profitiert hatten. Weiterhin zeigt es, dass vier Wochen diskontinuierliche 
Hypoxie möglicherweise nicht genügen um eine physiologische Adaptation zu erwirken. 
Athleten sollten sich dessen bewusst sein, bevor sie sich entscheiden die 
Unannehmlichkeiten eines Höhentrainings auf sich zu nehmen. 
 
Insgesamt zeigen die vorliegenden Resultate, dass die pulmonale Vasokonstriktion, nicht aber 
die verminderte cerebrale Oxygenierung VO2max in Hypoxie beeinträchtigen. Weiterhin 
deuten sie darauf hin, dass Höhentraining nach der „Hoch leben – Tief trainieren“ Strategie 
keine grössere Leistungssteigerung zur Folge hat als konventionelles Ausdauertraining.   
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1. Introduction 
1.1 Background 
The reduced O2 availability in hypoxia has a variety of effects on the human organism 
whereof one of the most noticeable is an impairment of aerobic exercise capacity. While the 
extent of this is largest in the initial phase of the hypoxic exposure, it attenuates with time as 
different physiological adaptive mechanisms partially restore uptake and transport of O2 to the 
skeletal muscles. 
 
The factors underlying the impeding impact of hypoxia have traditionally been of great 
interest in medicine and physiology as these do not only affect healthy individuals at altitude, 
but also a large number of patients suffering from conditions that abate internal O2 availability 
(55). However, despite a long history of research (25, 27, 134) our knowledge in this field 
remains far from complete. 
 
The purpose of the present PhD-project was to gain new insights into the interaction between 
hypoxia and aerobic exercise. To better understand the limitations induced by acute hypoxia, 
the contributions of two mechanisms other than those conventionally assumed responsible 
were investigated. Regarding the effect chronic hypoxia, the process of acclimatization and 
the resulting implications for subsequent sea level performance were studied in endurance 
athletes conducting the contemporary form of altitude training. 
After a brief review of the present state of knowledge in each respective field, the results are 
presented and discussed in five manuscripts (102, 114-117), four of which are to date in press 
or published in peer-reviewed journals. 
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1.2 Acute hypoxia and aerobic exercise 
The incapacitating effect of hypoxia has been recognized ever since humans started to ascend 
to altitude, but for a long time the underlying mechanisms were not understood. In the 
beginning of the 20
th
 century systematic investigations identified the reduced partial pressure 
of O2 (PO2) rather than the barometric pressure per se as the perpetrator (35, 143), and 
subsequently a long list of studies have revealed how this may impair aerobic exercise 
capacity. 
 
Direct implication of a reduced PO2 for aerobic exercise 
Performance in tasks that rely on aerobic metabolism is related to three components: i) 
maximal oxygen uptake (VO2max), which sets the notional upper limit for aerobic 
performance, ii) the fraction of VO2max that is sustainable for the required time and yields the 
“performance VO2” and iii) exercise efficiency, which determines the work rate that is 
generated at the O2 cost corresponding to the performance VO2 (figure 1) (17, 65). While the 
latter two components are not affected by acute hypoxia (42, 140) VO2max decreases with the 
inspired PO2 in a curvi-linear relationship (figure 2) (30, 34, 44, 92). To understand how acute 
hypoxia impairs aerobic exercise it is thus necessary to distinguish the factors determining 
VO2max and how they are affected by the reduction in PO2. 
During incremental whole body exercise pulmonary VO2 rises linearly due to an accelerating 
aerobic metabolism in the active skeletal muscles (59). However, as VO2max is reached near 
maximal effort, the VO2 curve plateaus and becomes irresponsive to further elevations in 
workload (13, 59). This indicates failure to either increase muscular O2 supply or O2 
consumption by the mitochondria. If an exercise task involves a large muscle mass, as it is 
required for the achievement of whole body VO2max, mitochondrial capacity clearly exceeds 
the highest rate of O2 delivery (20) and thus VO2max is limited by O2 transport rather than 
utilization. 
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To reach the muscle‟s mitochondria O2 is carried along a cascade of four consecutive 
processes, i.e. pulmonary ventilation, alveolar-capillary diffusion, convective transport by the 
circulation and capillary-mitochondrial diffusion (27, 133). While pulmonary ventilation and 
convective O2 transport are active processes that are stimulated as the demand for O2 
increases, diffusive transport at the pulmonary and the muscular sites is passively driven by 
the PO2 gradient over the according membranes. These steps are challenged during exercise 
as the increasing cardiac output shortens capillary transit time, i.e. the time available for O2 
diffusion (131, 132). During normoxic exercise the hyperpnoea-related increase in alveolar 
PO2 generally accelerates trans-alveolar diffusion sufficiently to prevent a significant drop in 
arterial O2 saturation (SaO2) (17, 91). In contrast, capillary-mitochondrial diffusion is more 
sensitive to shortened transit times and may limit O2 transport (106, 131), but probably only 
to a small extent (33, 109). Accordingly, the bottleneck is the convective process that 
connects the two sites of diffusive transport and as such, an individual‟s VO2max is mainly 
determined by the capacity to increase cardiac output (17, 68, 109, 110). However, this order 
shifts in acute hypoxia where, despite an immediate reflex stimulation of pulmonary 
ventilation (139), alveolar PO2 decreases (74, 93). Due to the passive nature of diffusive 
transport into the pulmonary capillaries arterial PO2 diminishes in a direct response hereof. 
Furthermore, the narrower alveolar-capillary PO2 gradient induces a growing pulmonary 
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diffusion limitation as cardiac output rises (25, 27, 54). The combination of these two factors 
leads to a progressive decrease in arterial O2 content (caO2) during incremental exercise. At 
submaximal workloads this is compensated for by an elevation of cardiac output which 
preserves O2 delivery to the skeletal muscles (25, 37). However, as during maximal exercise 
neither cardiac output (110) nor the distribution of blood flow (25) are affected by acute 
hypoxia the lower caO2 abates convective O2 transport in direct proportion. This is further 
aggravated in hypoxia corresponding to altitudes > 4,500 m where maximal cardiac decreases 
in response to PO2 (25, 125). Although the reason for this is not entirely clear it may account 
for approximately one third of the reduction in VO2max in severe hypoxia (25). However, a 
contrasting viewpoint postulates that the lower cardiac output is not restrictive but rather a 
protective down-regulation that prevents excessive diffusion limitation at the pulmonary and 
muscular sites (135). As such it may prohibit increases in cardiac output that result in no gain 
or even a loss in mitochondrial O2 supply. 
Similar to normoxia it is controversial whether capillary-mitochondrial diffusion limits 
VO2max in hypoxia (109, 132). A more important role is indicated as in severe hypoxia, an 
erythropoietin-induced elevation of caO2 fails to improve VO2max (98). This is in contrast to 
normoxia (78, 79, 98) or mild hypoxia (98) and may suggest that skeletal muscle O2 uptake in 
severe hypoxia is limited by the capillary-mitochondrial diffusion gradient rather than by the 
convective transport rate. In contrast however, other studies have reported the relationship 
between convective O2 supply and muscular O2 consumption to be independent of PO2 which 
argues against a major role of peripheral diffusion limitation also in hypoxia (25, 80). 
In summary, VO2max is determined by the O2 supply to the mitochondria of the exercising 
muscle cells. In normoxia this is mainly confined by the capacity to increase cardiac output 
although a contribution of peripheral diffusion limitation cannot be ruled out. In hypoxia, the 
lower alveolar PO2 and a resulting pulmonary diffusion limitation decrease arterial O2 content 
and thus convective O2 transport. As altitude exceeds 4,500 m, this is further exacerbated by a 
reduction in maximal cardiac output and potentially a capillary-mitochondrial diffusion 
limitation. All these factors together decrease mitochondrial O2 supply and thus VO2max. 
 
Although the mechanisms introduced above are commonly accepted as the main reason for 
the limited aerobic exercise capacity in acute hypoxia, this does not exclude a potential 
contribution of more indirect factors. Particularly over the last decade growing evidence has 
suggested that the intrinsic response of the pulmonary circulation to acute hypoxia may 
provoke additional impairment. Furthermore, similarly recent studies have revealed a direct 
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impact of hypoxia on the central nervous system which may accelerate fatigue development 
independent of mitochondrial O2 supply. The first two aims of the present PhD-thesis 
focussed on these mechanisms as specified in the following paragraphs. 
 
Aim 1: Limitations induced by the pulmonary circulation 
The pulmonary circulation responds to a decrease in alveolar PO2 by hypoxic pulmonary 
vasoconstriction (HPV) (127) in the pre-capillary resistance vessels (119). This reflex leads to 
optimized ventilation/ perfusion matching by reducing blood flow to poorly ventilated alveoli 
(85). However, during hypoxic exposure PO2 declines in all alveoli which induces a global 
instead of local vasoconstriction. As a results, pulmonary artery pressure (PAP) rises (86, 87) 
to an extent that is depending on the degree of hypoxia (53) and individual responsiveness 
(95) but potentially even beyond the threshold that defines severe pulmonary hypertension 
(87). Since in patients the latter induces exercise intolerance as a primary symptom (31, 137, 
138) the HPV-induced rise in PAP might limit healthy humans by the same mechanisms: 
First, the blood flow resistance associated with the constricted pulmonary vasculature may 
diminish right ventricular stroke volume (89) which may translate into a reduced left 
ventricular diastolic filling and, by the Frank-Starling mechanism, constrain the capacity to 
increase cardiac output (90). Second, the elevated PAP may amplify arterial hypoxia by 
promoting ventilation/ perfusion mismatch as the global constriction of pulmonary resistance 
vessels impairs the ability to adjust blood flow to local differences in alveolar PO2 (124, 128). 
Experimental evidence for a limiting role of the HPV was provided by several studies which 
attenuated PAP by pharmacological interventions (38-40, 48, 88, 97). The most frequently 
used agent for this purpose is the phosphodiesterase-5-inhibitor Sildenafil. This vasodilator 
has been reported to increase maximal cardiac output and exercise capacity in both, acute and 
chronic hypoxia, whereas SaO2 was elevated in acute hypoxia only (48). As the latter did not 
seem to be a requirement for the performance gain it was concluded that the ergogenic action 
was rather based on right ventricular relief allowing for a higher cardiac output. Similar 
conclusions were drawn in two successive studies that applied endothelin receptor antagonists 
to reduce PAP (38, 88) which increased VO2max without affecting SaO2. In contrast, Faoro 
and colleagues observed a beneficial effect of Sildenafil only when an elevated SaO2 was 
present at the same time and thus attributed it to changes in diffusive rather than convective 
O2 transport (39). This was partially supported by another study that confirmed the positive 
effects of Sildenafil on SaO2 and VO2max whereas submaximal cardiac output remained 
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unchanged (97). Nevertheless, this could not exclude that the treatment affected cardiac 
output at higher workloads and thus may not rule out the limiting effect of right ventricular 
afterload that was suggested earlier. Taken together the ergogenic impact of pulmonary 
vasodilators in hypoxia indicates a limiting role of the HPV although the individual 
contribution of underlying mechanisms remains to date controversial. 
Further specific evidence in this area was collected in subjects with a susceptibility to high 
altitude pulmonary edema (HAPE) (16). These persons are characterized by an excessive 
HPV that may cause pulmonary vessel leaking and the formation of extravascular fluid 
accumulation (15). Direct comparison between HAPE-susceptible and normal individuals 
therefore offers the possibility to examine the implications of different degrees of HPV 
independent of pharmacological vasodilation. Indeed, in a study that tested HAPE-susceptible 
subjects at 4,559 m the exercise limitation was larger than expected in normal individuals (73, 
77) and attenuated by pulmonary vasodilation induced by the glucocorticoid Dexamethasone 
(40). However, although the pronounced exercise impairment is interesting it has to be 
interpreted with caution as comparisons between studies may be affected by different 
protocols and measurement techniques. Furthermore, as subjects were tested only a few hours 
after a strenuous two day ascent to 4,559 m exercise capacity might have been attenuated by 
preliminary fatigue (40). Finally, the trials were conducted in a supine position which may 
have in particular limited HAPE-susceptible subjects by spreading out subclinical pulmonary 
fluid accumulated in the basal region of the lung (114). 
The first aim of this PhD-project was to confirm the previous observations in HAPE-
susceptible individuals independent of these shortcomings. This was performed in two steps: 
First, by ensuring that the ergogenic effect of pulmonary vasodilation induced by 
Dexamethasone persists during a conventional cycle ergometer test and following a longer 
recovery period after the ascent to altitude. Second, by inclusion of normal individuals and 
direct comparison to the HAPE-susceptible subjects in the same study design. 
The obtained results are presented in two manuscripts (114, 115) one of which (114) is to date 
published in a peer-reviewed journal whereas the other one  will be submitted as a short report 
in the near future. 
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Aim 2: Limitations induced by the cerebral circulation 
Strenuous exercise induces muscle fatigue that manifests by a reduction in maximal voluntary 
force generation (45). Our initial understanding of the factors leading to this phenomenon was 
largely based on the ideas of the English Nobelist Archibald Hill. He suggested that during 
fatiguing muscle work, a mismatch between O2 demand and supply leads to biochemical 
perturbations within the myocytes that progressively constrain the shortening process (56-58). 
In accordance with this notion, performance in intense aerobic exercise tasks is to a large 
extent determined by the capacity to increase muscular O2 supply (17, 68, 109, 110). 
However, a few years before Hill‟s hypothesis the Italian physiologist Angelo Mosso had 
introduced the concept that a central component, i.e. a process located within the brain, 
contributes to the development of muscle fatigue (84). Mosso interpreted this “central fatigue” 
as a protective mechanism that extorts abortion of exercise before muscular perturbation 
becomes excessive and may lead to tissue damage. Although this approach did initially not 
receive the same acceptance as Hill‟s model, it has attracted new interest as recent 
experiments provided evidence for central fatigue as indicated by a progressive decrease in 
motoneural drive despite a persisting requirement for force generation (46). Numerous studies 
have further indicated that the loss in voluntary force generation during fatiguing exercise is 
induced by the combination of a peripheral and a central component i.e. changes in the 
biochemical milieu within the myocytes (3, 4) and a reduced motoneural fibre recruitment (9). 
If the two components appeared independently they could easily be assessed by 
electromyography (EMG) as illustrated in figure 3 (49). However, as during exercise both 
components develop simultaneously, a more sophisticated approach needs to be applied. The 
most commonly used technique requires subjects to perform a maximal muscle contraction 
whereupon the motoneuron is magnetically stimulated (107). This generates supramaximal 
muscular fibre recruitment which results in a twitch-like increase of the maximal force output 
even in the unfatigued muscle (figure 4) (81). As the experiment is repeated after exercise a 
reduced force generation during supramaximal fibre recruitment illustrates the peripheral 
component of muscle fatigue (107). On the other hand, a larger difference between the 
voluntary and the magnetically induced supramaximal force output reveals the contribution of 
a diminished central motor drive, i.e. central fatigue. Such an experimental approach has 
repeatedly provided evidence for central fatigue to occur not only during resistance type 
exercise (14, 136) but also during strenuous endurance exercise (32, 67). 
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In line with Mosso‟s initial assumption central fatigue might indeed be a protective 
mechanism to prevent overstrain of the muscle fibres (84). Experiments during high-intensity 
cycling have revealed an individual threshold for peripheral fatigue development that could 
not be exceeded voluntarily (5, 9, 24). Instead, subjects subconsciously adapted their power 
output in time trials accordingly (11) whereas in fixed workload tests they exhausted as 
peripheral fatigue reached the critical threshold (9). The underlying regulation seems to 
depend on inhibitory feedback from metabosensitive muscle afferents that increase their 
discharge rate as fatigue related metabolites accumulate (6). This was experimentally 
demonstrated in subjects performing cycling time trials while the afferents from the 
locomotor muscles were pharmacologically blocked (7). Deprived from inhibitory feedback 
the central nervous system increased the motor drive which produced substantially more 
severe muscle fatigue than in the placebo trial. In fact, this study illustrated the importance of 
a protective role of central fatigue as, after the test, muscular exhaustion was so exaggerated 
that subjects temporarily experienced problems with simple muscular tasks such as walking or 
standing (7). 
Although at first sight the role of O2 appears minor in the process of central fatigue, the 
contrary is true, as hypoxia accelerates central fatigue development in different ways. First, 
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hypoxia increases the firing rate of the metabosensitive muscle afferents and thus the 
inhibitory feedback to the central nervous system (8, 10). This is the result of both, an 
increased resting discharge frequency, i.e. an effect on the nerves that is independent of 
exercise (60), and a faster accumulation of fatigue related metabolites during muscular work 
(72). Second, indirect evidence suggests an impeding influence of hypoxia on the supraspinal 
structures of the central nervous system (8, 121). Oxygenation of the cerebellum is 
determined by the product of arterial O2 content and cerebral blood supply and both are 
negatively affected by hypoxia (64, 94): First, caO2 is reduced which attenuates cerebral 
oxygenation if not compensated for by a higher blood supply (122). Second, arterial hypoxia 
stimulates peripheral chemoreceptors, causing reflex hyperpnoea (66) that partially restores 
arterial oxygenation (27) but also decreases arterial PCO2 (125). As the latter is a potent 
regulator of cerebral artery vessel tone (63) hyperventilatory hypocapnia entails a reduction in 
cerebral blood supply (64, 122). Both mechanisms are further accelerated by exercise which 
decreases caO2 (30, 44, 92) and induces further hyperventilation (66). The resulting decline in 
cerebral oxygenation might induce central fatigue independent of inhibitory muscle afferents 
(8, 10). This was suggested based on experiments where subjects performed exhaustive 
exercise in severe hypoxia. EMG recordings revealed that exhaustion was induced by a 
progressive decrease in central motor drive that occurred at a lower degree of peripheral 
fatigue than in normoxia (12, 121). However, as subjects were switched to hyperoxic 
breathing immediately before exhaustion cerebral oxygenation normalized within seconds 
which restored central neural drive and allowed subjects to continue exercising until the 
individual critical threshold in peripheral fatigue was reached. Nevertheless, it had to be 
acknowledged that hyperoxic breathing concomitantly restored oxygenation in the entire 
organism and that the individual effect of cerebral re-oxygenation could thus not be 
determined. Accordingly, Subudhi and colleagues attempted a specific re-oxygenation of the 
brain by enhancing cerebral blood flow with inspiratory CO2 administration (123). This 
indeed elevated cerebral oxygenation as compared to sham treatment but, contrary to the 
hypothesis, did not increase VO2max. However, the experiments were carried out in severe 
hypoxia corresponding to 4,875 m where a reduction in cardiac output (25) and peripheral O2 
diffusion limitations (98, 132) may have overruled a potential benefit of a restored cerebral 
oxygenation. 
The second aim of this project was therefore to examine the effect of inspiratory CO2 
administration during exercise in more moderate hypoxia. We expected that in the absence of 
cardiac restrictions and potential peripheral diffusion limitations the increase in cerebral 
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oxygenation may increase VO2max. The collected results are enclosed in a manuscript that is 
presently in press in a peer-reviewed journal (117). 
 
1.3 Chronic hypoxia and aerobic exercise 
As indicated, the exercise impairment in acute hypoxia is mainly the consequence of a 
reduced caO2 that compromises convective O2 transport. However, as exposure extends this is 
counteracted by an enhanced renal erythropoietin release (93, 96) which raises serum 
erythropoietin concentration to peak within 24-48 hours where after it slowly decreases to 
stabilize slightly above initial levels (1). The circulating erythropoietin progressively restores 
caO2 by inducing polycythemia. This is initially entirely related to a contraction of plasma 
volume (118, 142) whereas erythropoiesis may increase the total volume of red blood cells 
(RCV) after several weeks (93, 96). 
Although these haematological adaptations elevate caO2 to eventually match or even exceed 
the values in normoxia the resulting impact on VO2max is smaller than expected. Particularly 
in hypoxia corresponding to altitudes > 4,000 m acclimatization has little or no effect on 
VO2max (18, 26, 28, 80) whereas in more moderate hypoxia the gain is larger (113). Similar 
observations were made in acute hypoxia if RCV was preliminarily increased by autologous 
blood transfusion (104, 105) or erythropoietin treatment (75, 98). This indicates that the 
normalization of caO2 only benefits VO2max in moderate hypoxia whereas other factors offset 
the ergogenic impact in severe hypoxia (26). 
In contrast to these inconsistent consequences for VO2max, the acclimatization process 
improves submaximal exercise capacity in all degrees of hypoxia (62, 82, 113). It is not 
entirely clear why the improvements persist in severe hypoxia despite an unchanged VO2max 
but they might be related to a reduced perceived exertion during exercise as the increased 
caO2 reduces the cardiac output required to still a given muscular O2 demand. 
The progressive restoration of submaximal exercise capacity is of high relevance for athletic 
performance at altitude and accordingly hypoxic exposure is a widespread preparative 
measure particularly in endurance sport. However, its application is not confined to the 
preparation for competitions at altitude as an erythropoietic elevation of the O2 transport 
capacity is similarly ergogenic at sea level. This was clearly demonstrated following 
erythropoietin treatment (79, 98) or autologous blood transfusions (22, 36) whereas a 
reduction of RCV by phlebotomy has the contrary effect and reduces exercise capacity (36). 
As any manipulation of RCV is banned by the world anti-doping agency (WADA) endurance 
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athletes frequently attempt to stimulate erythropoiesis by hypoxia. This has led to the 
development of different forms of so called altitude training (76). The last aim of the present 
project was to examine the effects of the most contemporary altitude training strategy on 
highly trained endurance athletes, as explained below. 
 
Aim 3: The effect of Live High-Train Low on elite athletes 
The speculation that hypoxic exposure benefits sea level performance was initially inspired by 
the outstanding success of Eastern African runners who live and train at elevated altitude in 
their home countries (141). The classical altitude training concept attempted to copy these 
conditions and required athletes to spend several weeks of their preparation at moderate 
altitude (Live High – Train High, LHTH). However, despite the persisting popularity of 
LHTH its efficiency has always been subject to discord (41). Well-controlled studies in this 
field are scarce and although some of them observed an ergogenic effect (23, 83) others could 
not confirm this (2, 126). A potential explanation for the absence of performance gains 
following LHTH was provided by the findings of Levine and Stray-Gundersen (69). Although 
in their study LHTH elevated RCV and, in direct proportion, VO2max of 13 sub-elite runners, 
this did not translate into a better 5 km running performance. According to the authors this 
may have been due to the impeding effect of even moderate hypoxia which lowered absolute 
training intensity during the LHTH period and may have led to a loss of muscular 
conditioning (69, 71). To avoid this process they introduced the Live High – Train Low 
(LHTL) strategy where athletes reside at similar altitude but train as close as possible to sea 
level to preserve training intensity (71). The applicability of LHTL was tested in the before 
mentioned study where another group of runners lived at 2,500 m but was transported to 
1,300 m for daily training (69). This induced the same elevation of RCV and VO2max as 
LHTH suggesting that the discontinuous hypoxic exposure was adequate to stimulate 
erythropoiesis. However, following LHTL these changes resulted in a better 5 km running 
performance presumably as training intensity could be preserved at the lower altitude. Similar 
findings were later obtained in some (21, 47, 103), but not all studies (100, 101), that induced 
the hypoxic stimulus by normobaric hypoxia in appropriate facilities. This modification 
became popular as it avoids the logistic effort of daily travelling and allows to conduct LHTL 
in countries that lack suitable training locations at altitude. Nevertheless, despite the 
promising findings of particularly the initial LHTL study (69) and the perspicuous rationale 
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for the superiority of this training strategy, the usefulness for endurance athletes is still 
debated due to several issues: 
First, the efficiency of LHTL was never demonstrated in a placebo controlled study design. 
This is a serious concern as, even though the expected gains are substantial from an elite 
athlete‟s perspective (61), they are physiologically marginal (19, 52) and in the same range as 
a placebo-effect may enhance endurance performance (29). Given the considerable financial 
costs of appropriate facilities as well as the time exposure and social constraints associated for 
athletes it is inevitable to confirm that LHTL is not just an expensive and inconvenient 
placebo treatment. 
Second, the impact of LHTL has barely been examined in true elite athletes. As indicated, 
expected performance gains are minor and thus this training form seems not relevant for sub-
elite athletes who preserve the capacity to improve by conventional measures. In contrast, 
elite athletes have often reached the limit of physiological adaptability to normal training 
stimuli (50, 99). As in these individuals even the slightest difference may determine between 
winning and losing (61) they are the appropriate target group for LHTL and studies should 
include subjects accordingly. 
Finally, beyond the pivotal discord about the efficiency of LHTL is a widespread 
disagreement regarding the underlying mechanisms (52, 70). The most popular explanation is 
the erythropoietic approach which attributes performance gains to an optimized convective O2 
transport capacity (69, 70). Nevertheless, this is solely based on correlative analyses and 
theoretical reasoning and lacks direct evidence. Furthermore, different studies have reported 
LHTL to benefit endurance performance independent of changes in RCV but by improving 
exercise economy (51, 112). Such an adaptation allows athletes to race at the same perceived 
intensity while producing a higher speed which is an enormous advantage (65). Similar to 
other potential effects of LHTL, however, an improved exercise economy is not a consistent 
finding and lacks confirmation from a placebo-controlled study. 
The third and final aim of this project was to resolve these limitations of previous LHTL 
studies by conducting a placebo-controlled trial including elite athletes as subjects. 
Furthermore specific experimental interventions were included to establish the mechanisms 
that underlie potential performance gains. The observations made in this study are presented 
in two manuscripts that are published in peer-reviewed journals (102, 116).  
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Dexamethasone Improves Maximal Exercise Capacity
of Individuals Susceptible to High Altitude Pulmonary
Edema at 4559m
Christoph Siebenmann,1,2 Konrad E. Bloch,2,3 Carsten Lundby,2 Yvonne Nussbamer-Ochsner,3
Miche`le Schoeb,4 and Marco Maggiorini4
Abstract
Siebenmann, Christoph, Bloch, Konrad E., Lundby, Carsten, Yvonne Nussbaumer-Ochsner, Miche`le Schoeb, and
Marco Maggiorini. Dexamethasone improves maximal excercise capacity of individuals susceptible to high
altitude pulmonary edema at 4559m. High Alt. Med. Biol. 12:169–177, 2011.—We have previously demonstrated
that prophylactic intake of dexamethasone improves maximal oxygen uptake (Vo2max) in high altitude pul-
monary edema (HAPE) susceptible subjects 4 to 6 h after a 2-day climb to 4559m. However, since with this
ascent protocol HAPE usually develops after the ﬁrst night at 4559m or later, we hypothesized that a continued
dexamethasone prophylaxis would result in an even more pronounced improvement of Vo2max after an ad-
ditional night at high altitude.
Vo2max of 24 HAPE susceptibles was evaluated on a bicycle ergometer at an altitude of 490m and at 24 h after
rapid ascent to 4559m. Subjects were divided into two groups: The control group (n¼ 14) performed both tests
without dexamethasone, whereas the dexamethasone group (n¼ 10) received dexamethasone 8mg twice a day
(b.i.d), starting 24 h prior to ascent.
At 4559m, Vo2max was 61% 6% of the baseline value in the control group and 70% 9% in the dexa-
methasone group ( p¼ 0.025). Similarly, O2 pulse (Vo2/heart rate) was 68% 7% and 77% 11% of baseline,
respectively ( p¼ 0.043). Arterial O2 saturation at maximal exercise did not differ between groups, whereas at
rest it was 83% 10% in the control group and 91% 4% in the dexamethasone group ( p¼ 0.009).
Dexamethasone prophylaxis increased Vo2max of HAPE-susceptible individuals after the ﬁrst night at 4559m
without affecting arterial O2 saturation at maximal exercise. This might be explained by a sustained effect of
dexamethasone on maximal cardiac output and pulmonary O2 diffusion, both resulting in enhanced convec-
tional O2 transport to the locomotor muscles.
Key Words: hypoxia; Vo2max; pulmonary circulation
Introduction
Maximal O2 uptake (Vo2max) is reduced in acutehypoxia (Wagner, 2000; Calbet and Lundby, 2009)
owing to two main mechanisms (Calbet et al., 2003): First, the
arterial Po2 (Pao2) is decreased due to both a lower alveolar
Po2 and a resulting pulmonary diffusion limitation for O2
(Wagner, 2000; Calbet et al., 2003; Lundby et al., 2006). Sec-
ond, maximal cardiac output is reduced in severe hypoxia
owing to a decrease in stroke volume and maximal heart rate
(HR) (Calbet et al., 2003). Each mechanism contributes to a
lower O2 delivery to the locomotor muscles and therefore a
decline in Vo2max.
The decline in Vo2max might be even more prominent in
persons who develop a subclinical (Cremona et al., 2002) or
overt high altitude pulmonary edema (HAPE) (Bartsch et al.,
2003). HAPE is a noncardiogenic edema, typically occurring
after rapid ascent to altitudes higher than 2500m (Bartsch
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et al., 2003). In individuals susceptible to HAPE (HAPE-s), the
mechanism of HAPE pathogenesis is an excessive and inho-
mogeneous increase in pulmonary artery resistance because
of vasoconstriction in response to acute hypoxia (Bartsch
et al., 2005). This leads to overperfusion of remaining patent
vessels and subsequent injury of pulmonary capillary walls,
with leakage of red blood cells and proteins into the airways
and alveoli (Hultgren, 1996). Although HAPE is a life-
threatening and rare disease, subclinical pulmonary extra-
vascular ﬂuid accumulation is more prevalent and may be
present in about 75% of non-HAPE-s mountaineers examined
shortly after arrival at an altitude of 4559m (Cremona et al.,
2002).
The pathogenesis of HAPE may potentiate the Vo2max-
reducing factors in acute hypoxia. Interstitial pulmonary
edema elongates the diffusion distance of O2 from the alveoli
into the pulmonary capillaries (Steinacker et al., 1998) and
negatively inﬂuences ventilation–perfusion matching, there-
by deteriorating respiratory efﬁciency during heavy exercise
(Podolsky et al., 1996). All these factors result in a more pro-
minent decrease in Pao2. In addition, excessive elevations in
pulmonary arterial resistance could increase the afterload of
the right ventricle and reduce its stroke volume, thereby de-
creasing left ventricular preload and maximal cardiac output
(Ghofrani et al., 2004).
An efﬁcient intervention to avoid health threat in climbers
and travelers that do not have the opportunity to acclimatize
before an ascent to altitudes higher than 2500m is the pro-
phylactic administration of dexamethasone, a synthetic glu-
cocorticoid. Dexamethasone is known to be effective as a
prophylaxis against acute mountain sickness (AMS) ( Johnson
et al., 1984) and even superior to the broadly used carbonic
anhydrase inhibitor acetazolamide (Ellsworth et al., 1991). If
treatment is started prior to exposure to hypoxia, dexameth-
asone prophylaxis decreases pulmonary arterial resistance
(Maggiorini et al., 2006) and enhances alveolar ﬂuid clearance
(Folkesson et al., 2000; Noda et al., 2003; Guney et al., 2007).
Both mechanisms contribute to a lower incidence of HAPE.
Dexamethasone was also found to increase resting Pao2 in
acute hypoxia (Maggiorini et al., 2006).
The effect of dexamethasone on HAPE-s has been broadly
examined in resting conditions; however, the inﬂuences on
exercise performance are poorly explored. Fischler and col-
leagues (Fischler et al., 2009) reported that dexamethasone
taken before a 2-day ascent to the Capanna ReginaMargherita
research facility (Italy, 4559m) increased the Vo2max of
HAPE-s subjects measured 4 to 6 h after arrival. However,
since HAPE normally develops after 2 to 5 days of hypoxic
exposure (Bartsch et al., 2005) and, in our experience with this
ascent proﬁle, usually after the ﬁrst night at the Margherita
hut or later, the adverse impact of HAPE pathogenesis on
Vo2max may be more pronounced after a longer period of
hypoxic exposure, which may enhance the beneﬁcial effect of
dexamethasone. We therefore tested the hypothesis that the
beneﬁt of a dexamethasone prophylaxis on Vo2max would be
maintained and more pronounced in HAPE-s subjects after
staying an additional night at the Margherita hut.
Methods
The current study includes 16 of 25 HAPE-s mountaineers
who initially participated in a randomized, double-blind,
placebo-controlled study in 2007. Because of 9 dropouts due
to bad weather conditions and incapacitating acute mountain
sickness (AMS) before arriving at 4559m, 8 additional HAPE-
s mountaineers were recruited according to the same inclu-
sion criteria in a complementary open-label study in 2009.
Both studies followed similar protocols and were approved
by the Ethical Committee of the University of Zurich and
conformed to the Declaration of Helsinki. Subjects gave
written informed consent to participation.
Subjects
In total, 24 subjects were ﬁnally included into the present
analysis. Criteria of inclusion was susceptibility to HAPE,
which was deﬁned by a history of radiologically or clinically
diagnosed HAPE and conﬁrmed in an interview by a physi-
cian with long-time experience in high altitude medicine.
Criteria of exclusion included age below 18 and above 65 yr,
chronic intake of medication, or previous diagnosis of car-
diopulmonary and other chronic diseases. Further, we ex-
cluded mountaineers who had spent more than 5 nights at an
altitude higher than 2500m within the last 30 days of the
beginning of the investigation. Anthropometric data of the
subjects included in the study are summarized in Table 1.
Protocol
Baseline examinations were conducted at the University
Hospital of Zurich (490m). Subjects spent 2 days in the hos-
pital performing a baseline cardiopulmonary exercise test
(CPET) in the late afternoon (2007) or during the course of the
morning (2009). In both settings, CPETwas performed at least
2 h after the last meal.
Two to three weeks after baseline measurements, all study
participants traveled to Alagna (Italy, 1205m) in groups of 2
to 4. From there theywere carried by cable car to an altitude of
2900m. They continued by foot to the Gnifetti hut (3647m),
where they arrived in the late afternoon and spent the night.
The following morning they reached the Margherita hut
(4559m) after 4 to 6 h of ascent. Throughout the entire trip, all
subjects were accompanied by a professional mountain guide.
CPET was performed the morning following night 1 spent at
the Margherita hut. Subjects then stayed at the hut 3 addi-
tional consecutive nights for further research and climbed
back down in the morning of day 5.
Medication
The 16 subjects from the 2007 study were randomized to
receive either 8mg dexamethasone b.i.d (Fortecortin, Merck,
Table 1. Anthropometric Data of the Subjects
Control group
Dexamethasone
group p-values
Number of
subjects
14 10
Male 9 8
Female 5 2
Age (years) 45 8.6 47 9.6 0.51
Height (m) 1.74 0.08 1.72 0.05 0.34
Weight (kg) 70.2 7.2 75.7 12.9 0.31
BMI (kg/m2) 23.1 1.5 25.5 3.7 0.15
Control group¼untreated group; Dexamethasone group¼
Dexamethasone-treated group; BMI¼Body mass index.
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Whitehouse, NJ, USA) (dexamethasone group, n¼ 10) or
placebo (control group, n¼ 6) during their stay at high
altitude, with treatment beginning 24 h prior to ascent.
They started intake autonomously, but the remaining num-
ber of pills and further intake were controlled at the
Margherita hut. Dexamethasone and placebo were packed
into identical white capsules so that neither subjects nor in-
vestigators could distinguish between them. However, open-
labeled emergency treatment with dexamethasone was
always available for subjects of the control group presenting
with severe AMS.
The 8 additional subjects included in the 2009 open-label
study to increase the number of participants within the con-
trol group (ﬁnal n¼ 14) did not receive placebo or dexa-
methasone before CPET. As in the 2007 study, dexamethasone
was provided as emergency treatment. However, in both
years, no participant randomized to the control group re-
quired emergency treatment with dexamethasone before
CPET.
Assessment of AMS and HAPE
In the morning before CPET, AMS was assessed by the
Lake Louise protocol, which consists of an interview and a
clinical examination (for details, seeMaggiorini et al., 1998). A
score >4 was used as an indicator for AMS. Further, subjects
were regularly examined for symptoms and signs of HAPE.
These examinations included daily auscultation of the lungs
and chest radiography on the second day at the Margherita
hut.
Conduction of CPET
CPET was performed on an electronically braked bicycle
ergometer in an upright position (Cyclus 2, RBM Elektronik,
Leibzig, Germany). Subjects wore a face mask that covered
the mouth and nose for complete breath collection. Ampero-
metric solid-state electrolyte sensors continuously measured
O2 and CO2 concentration in the expired gas. Results were
monitored and saved as breath-by-breath values on a portable
computer. The utilized system (ZAN 600 USB, nSpire Health,
Louisville, KY, USA) was calibrated immediately before each
test. HR was detected by electrocardiogram (CardioCollect
12, Spacelabs Healthcare, Feucht, Germany), and peripheral
arterial O2 saturation (Spo2) was measured by pulse oximetry
(Masimo SET Radical, Inspiration Medical, Bochum, Ger-
many) on the subject’s earlobe. Estimated maximal voluntary
ventilation (MVV) was calculated as forced expiratory vol-
ume in 1 sec (FEV1)40 (ACCP, 2003).
Resting values were obtained with the subjects sitting still
on the bicycle for 2min. They then started exercising at a
workload (W) of 50 W that was increased by 10 to 40 W/ min
according to a progressive ramp protocol individually tai-
lored to lead to exhaustion within 8 to 12min (ACCP, 2003).
To maintain test duration, increases in work rate were ap-
proximately 30% lower at 4559m than at baseline (490m).
During the last minutes, subjects were vigorously motivated
to continue until maximal exhaustion. All subjects reached
maximal exhaustion according to standard criteria (ACCP,
2003).
Respiratory parameters of 2 subjects of the control group
could not be properly measured because of technical
difﬁculties while at 4559 m; therefore, these parameters,
along with the corresponding low-altitude values, were
discarded.
Statistical analysis
Data were analyzed using Statistica 6.0 (Statsoft, USA) To
evaluate differences between the two groups, the values at
high altitude were compared in percents of the values at low
altitude using a Mann–Whitney U test for nonparametric and
independent samples. The effect of the exposure to high alti-
tude within each group was evaluated by the Wilcoxon
matched pairs test. Results are given as mean SD; a p value
of <0.05 was considered statistically signiﬁcant.
Results
Baseline testing
Baseline examinations at 490m revealed that subjects were
healthy, with normal pulmonary functions and free of signs of
pulmonary hypertension. None were on any medications or
supplements that might interfere with our experiments. All
were able and motivated to perform CPET to complete ex-
haustion (Table 2).
Altitude exposure
Exposure to hypoxia was well tolerated by all subjects, and
they were able to perform the exercise trials (Table 2).
Nevertheless, Lake Louise scores evaluated in the morning
before CPET were 5.71 2.55 in the control group and
3.70 1.95 in the dexamethasone-group ( p¼ 0.036); a Lake
Louise score>4, indicating the presence of AMS,was found in
9 controls, but in only 3 subjects of the dexamethasone group.
No signs of HAPEwere observed in either group on the ﬁrst 2
days at the Margherita hut.
Resting HR was increased by 26% in the control group and
reduced by 2% in the dexamethasone group ( p¼ 0.007) from
baseline values, while resting Spo2 was 83% 10% in the
control group and 91 4% in the dexamethasone group, re-
spectively ( p¼ 0.009). Table 2 summarizes the CPET results
for both conditions and illustrates the inﬂuence of the rapid
ascent to 4559m on exercise capacity. In both groups, hypoxia
induced a substantial decrease in Vo2max. Nevertheless, the
respiratory exchange ratio (RER¼Vco2/Vo2) was similar to
baseline in both groups, indicating maximal effort at high
altitude despite the presence of AMS, especially in the control
group, and no signiﬁcant difference in RER between groups
was observed. Further, no correlation was found between
Lake Louise scores and RER (R2¼ 0.06).
Effects of dexamethasone prophylaxis
on maximal exercise capacity
To evaluate the inﬂuence of the dexamethasone prophy-
laxis on maximal exercise capacity, we compared the results
achieved at 4559m in percents of the baseline values (Table 3).
Compared with the control group, the decrease in maximal
workload (Wmax) was 7% smaller in the dexamethasone
group ( p¼ 0.004). This was accompanied by an almost 10%
smaller decrease in Vo2max in the dexamethasone group
( p¼ 0.025). Despite these differences, minute ventilation (Ve)
was similar between groups and to values obtained at low
altitude, as was Ve/Vo2. However, Ve/Vco2 at high altitude
was increased in both groups, whereas the increase was
16
almost 18% higher in the control group than in the dexa-
methasone group ( p¼ 0.0001). Tidal volume (VT) tended to be
larger in the dexamethasone group ( p¼ 0.050) in group
comparison, whereas it was reduced at high altitude in the
control group only.
At maximal exercise, neither HR nor Spo2 differed between
the groups. O2 pulse (Vo2/HR), an indirect measurement of
stroke volume (ACCP, 2003), was 67.7% 6.5% of the baseline
value in the control group and 76.6% 11.2% in the dexa-
methasone group ( p¼ 0.043). Individual responses in Wmax,
Vo2max and Spo2 to the hypoxic exposure are illustrated in
Fig. 1.
Figure 2 depicts the correlation between Vo2max and
Spo2 at 4559m, both expressed as percentages of the values
at low altitudes. A strong and signiﬁcant correlation was
present in the dexamethasone group, but not in the control
group.
Effects of the placebo treatment
To establish the effect of the placebo treatment that was
applied in 2007, but not in 2009, to subjects of the control
group, the hypoxic Vo2max of these two subgroups was
compared. In the placebo-treated control-group subjects of
2007, Vo2max was 60% 7% of the baseline value, whereas
control-group subjects of 2009 that did not receive placebo
obtained 62% 4% ( p¼ 0.7). Further, Vo2max in both sub-
groups was signiﬁcantly lower than in the dexamethasone
group.
Discussion
The purpose of the present study was to test the hypothesis
that a prophylactic oral administration of dexamethasone
8mg b.i.d, starting 24 h prior to ascent and maintained
throughout an overnight stay at 4559m, provides persistent
increases in hypoxic Vo2max in HAPE-s subjects. Our major
ﬁnding is that dexamethasone signiﬁcantly reduced the
hypoxia-related decline in Vo2max and resting Spo2. Further,
symptoms of AMS were signiﬁcantly abated in the dexa-
methasone group.
Our results conﬁrm and extend a previous study that re-
ported an improvement of Vo2max after rapid ascent to
4559m by prophylactic dexamethasone administration
(Fischler et al., 2009). However, in the earlier investigation,
CPET was conducted only 4 to 6 h after arrival at 4559m and
thus several hours or days before development of HAPE
generally occurs (Bartsch et al., 2005). To evaluate whether
continued administration of dexamethasone would provide
persistent and more distinct improvements of Vo2max, the
present results were collected following an additional 24 h of
hypoxic exposure. Indeed, in the earlier study, Vo2max of
untreated subjects decreased by 52% from values at low alti-
tude, and dexamethasone prophylaxis reduced this decrease
Table 2. Cardiorespiratory Parameters During Maximal Exercise at 490m and 4559m
Zurich, 490m Margherita, Day 2, 4,559m p-value for altitude effect
Group
Control
group
Dexamethasone
group
Control
group
Dexamethasone
group
Control
group
Dexamethasone
group
Vo2max [L/min] 3.58 0.69 3.59 0.78 2.17 0.43 2.47 0.44 0.002 0.005
Vco2 [L/min] 4.15 0.82 4.18 0.89 2.44 0.55 2.93 0.57 0.002 0.005
Wmax [W] 279 68 300 58 178 51 213 50 0.001 0.005
HR [1/min] 179 8 179 14 164 12 163 13 0.002 0.008
VE [L/min] 131 22.7 131 22.8 129 28.9 137 26 0.754 0.241
(% max) (85) (91) (93) (102)
MVV [L/min] 154 21.4 145 21.1 138 22.2 136 23.1 0.002 0.007
VE/Vo2 37.1 5.2 37.0 5.3 59.3 8.0 56.0 7.7 0.002 0.005
VE/Vco2 32.0 4.2 31.8 4.6 53.1 7.0 47.3 6.9 0.002 0.005
F [1/min] 45.8 5.4 47.1 7.5 50.4 9.8 50.8 9.2 0.060 0.074
VT [L] 2.87 0.43 2.83 0.60 2.58 0.49 2.74 0.51 0.002 0.445
F/VT [1/[L*min]] 16.3 3.6 17.9 6.6 20.4 6.4 19.5 6.7 0.005 0.093
RER 1.16 0.04 1.16 0.05 1.12 0.07 1.19 0.07 0.084 0.333
Spo2 [%] 96.1 2.7 97.6 2.2 72.6 14.2 74.0 8.98 0.001 0.005
Control-group¼untreated group; Dexamethasone-group¼Dexamethasone-treated group; Vo2max¼maximal O2 uptake; Vco2¼CO2
output; Wmax¼maximal workload; HR¼heart rate; VE¼minute ventilation; MVV¼ calculated maximal voluntary ventilation; F¼
respiratory frequency; VT¼ tidal volume; RER¼ respiratory exchange ratio (Vco2/Vo2); Spo2¼ arterial O2 Saturation.
Table 3. Cardiorespiratory Parameters
During Maximal Exercise at 4559m in Percents
of Baseline Values
Control group Dexamethasone group p-value
Vo2max [%] 60.9 5.7 69.7 8.6 0.025
Vco2 [%] 58.9 7.1 71.0 8.4 0.003
Wmax [%] 63.4 6.2 70.5 4.3 0.004
HR [%] 91.7 5.9 91.4 6.3 0.98
VE [%] 97.6 10.0 105.9 16.0 0.16
VE/Vo2 [%] 160.5 11.0 151.8 11.2 0.16
VE/Vco2 [%] 166.4 11.6 148.8 7.9 0.0001
F [%] 109.7 14.0 108.0 12.9 0.77
VT [%] 89.6 8.2 98.1 9.7 0.05
F/VT [%] 124.3 25.8 111.1 18.4 0.14
RER [%] 96.6 6.6 102.0 5.3 0.06
Spo2 [%] 75.5 13.6 75.7 7.9 0.58
Control group¼untreated group; Dexamethasone group¼
Dexamethasone-treated group; Vo2max¼maximal O2 uptake;
Vco2¼CO2 output; Wmax¼maximal workload; HR¼heart
rate; VE¼minute ventilation; MVV¼ calculated maximal volun-
tary ventilation; F¼ respiratory frequency; VT¼ tidal volume;
RER¼ respiratory exchange ratio (Vco2/Vo2); Spo2¼ arterial O2
Saturation.
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by 7% (Fischler et al., 2009). The present study shows that
dexamethasone reduced the 39% decrease in the control
group subjects by 9%. Furthermore, in the earlier study
(Fischler et al., 2009), dexamethasone treatment improved only
Vo2max, but not Wmax, which is surprising, because acute
hypoxia has been shown not to alter external work efﬁciency
(Lundby et al., 2007). In contrast, we observed dexamethasone
to improve Wmax and Vo2max similarly, which is in accor-
dance with an unchanged work efﬁciency (Vo2/W relation-
ship) in hypoxia. Our observations further extend the data by
Fischler and colleagues (2009); they tested their subjects in a
very unusual semirecumbent exercise position, whereas we
demonstrate beneﬁcial effects of dexamethasone on Vo2max in
a more familiar upright body position.
Generally, rapid ascent to high altitude is associated with
an impairment of Vo2max that becomes more severe with
increasing altitude. According to Fulco and colleagues (1998),
the expected decrease at 4559m compared with 490m is
about 30%. In accordance with this, previous observations on
Vo2max at the Margherita hut in non-HAPE-s subjects report
an average decrease of 31% (Lundby, 2008) or 21% (Lundby
et al., 2001). In the current study, rapid ascent led to a re-
duction of 39% in the control group. Although comparisons
between studies should be interpreted cautiously since dif-
ferent protocols and measurement techniques may inﬂuence
the outcomes, our results indicate a rather marked deterio-
ration in exercise capacity in untreated HAPE-s subjects
compared with normal individuals. This is in line with pre-
vious ﬁndings (Fischler et al., 2009) that reported an even
larger impairment, with untreated HAPE-s persons decreas-
ing by 52%. The additional impairment in that study may be
explained by the semirecumbent exercise position, which re-
duces Vo2max in healthy subjects at sea level (Pedersen et al.,
1996) and might additionally impair exercise in HAPE-s
subjects at high altitude by spreading extravascular ﬂuid,
originally trapped by gravity in the basal region of the lung,
over a larger pulmonary area. Further, CPET in the earlier
study was performed only a few hours after the subjects’ ar-
rival at the Margherita hut. The strenuous ascent on the test-
ing daymay have further contributed to the larger decrease in
maximal exercise capacity by fatiguing the subjects (Fischler
et al., 2009).
FIG. 1. Effect of acute hypoxia on treated and untreated subjects. Control group, untreated group; dexamethasone group,
dexamethasone-treated group; Vo2max, maximal O2 uptake; Wmax, maximal workload; Spo2, arterial O2 saturation during
maximal exercise; horizontal lines represent mean values at both altitudes; *p< 0.05 vs. mean value at 490m.
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What are the mechanisms by which dexamethasone in-
duces improvements in Vo2max in HAPE-s individuals?
During acute exposure to altitudes higher than 4000m, Vo2max
is mainly decreased by reductions in arterial O2 content and in
maximal cardiac output, both contributing to an attenuation
in convective O2 transport to the locomotor muscles (Calbet et
al., 2003). The dexamethasone prophylaxis may beneﬁcially
inﬂuence both of these factors: in acute hypoxia, dexametha-
sone acts as a vasodilator that abates the exaggerated rise in
pulmonary artery pressure that is characteristic for the de-
velopment of HAPE (Maggiorini et al., 2006). Increases in
hypoxic Vo2max with pulmonary vasodilatation have been
reported previously in studies that induced vasodilatation
with the phosphodiesterase-5 inhibitor sildenaﬁl (Ghofrani et
al., 2004; Richalet et al., 2005; Faoro et al., 2007). In these
studies, the performance-enhancing effect was explained by
either a reduction in right ventricular afterload, resulting in
higher cardiac output (Ghofrani et al., 2004), an improved
arterial oxygenation (Faoro et al., 2007), or both (Richalet et
al., 2005).
In the present data, O2 pulse is higher in the dexametha-
sone group than in the control group despite similar maximal
HR and Spo2. This suggests that the dexamethasone pro-
phylaxis led to an increase in maximal cardiac output, which
may enhance peripheral O2 delivery and therefore Vo2max.
Although there is some concern about using O2 pulse as an
approximation for stroke volume during exercise in hypoxic
environments owing to arterial O2 desaturation (ACCP, 2003),
we argue that the estimation remains applicable in our data,
because exercise Spo2 is very similar in both groups, indi-
cating a fairly equal amount of transported O2 in a given
volume of blood. Of interest, a similar exercise Spo2 was also
reported previously (Fischler et al., 2009) and is observed
despite the higher levels Vo2max and likely cardiac output
that may shorten pulmonary transit time and promote pul-
monary diffusion limitation in the dexamethasone group
(Hopkins et al., 1996). Therefore, the lack of a difference in
exercise Spo2 between subject groups in the present study
indicates an enhanced pulmonary O2 diffusion in the dexa-
methasone group, allowing for Spo2 to obtain similar levels as
in the controls despite higher exercise intensities, an expla-
nation that is supported by the ﬁnding of higher resting Spo2
in the dexamethasone group. An improved pulmonary O2
diffusion in subjects receiving dexamethasone may have
emerged from either an optimized blood distribution over
the pulmonary vessels, because subclinical HAPE has been
reported to promote ventilation–perfusion inequalities
(Podolsky et al., 1996), or from an elevated transpulmonary
O2 diffusion, resulting from a reduction in pulmonary extra-
vascular ﬂuid accumulation (Steinacker et al., 1998). These
explanations are supported by the lower Ve/Vco2 in the
dexamethasone group, which indicates a better ventilatory
efﬁciency with dexamethasone. Thus, the improvement in
Vo2max in the dexamethasone group may be explained by a
combination of both, an increase in maximal cardiac output,
and an improvement in pulmonary O2 diffusion. In favor of
this explanation, we observed that Vo2max and Spo2 were
signiﬁcantly correlated only in the dexamethasone group. A
hampered right ventricular performance with excessive
afterload may have caused exhaustion in the control group
before Spo2 became a limiting factor.
However, the question about the mechanism by which
dexamethasone may increase maximal cardiac output re-
mains debatable. As suggested in several similar studies ap-
plying different pulmonary vasodilators (Ghofrani et al.,
2004; Richalet et al., 2005; Faoro et al., 2009), a decrease in right
ventricular afterload may explain higher levels of cardiac
output. In turn, it has been proposed that the reduction in
maximal cardiac output in hypoxia may result from a cardiac
downregulation aiming to prevent an excessive widening of
the alveolar–arterial Po2 difference with decreasing pulmo-
nary transit times (Calbet et al., 2003). Therefore, an improved
pulmonary O2 diffusion may allow for cardiac output to ob-
tain higher levels before reaching the point where further in-
creases would result in no or even negative changes in
peripheral O2 delivery. This explanation is supported by the
ﬁnding that Spo2 was higher in the dexamethasone group at
rest, but did not differ between groups at maximal exercise
where a potential downregulation of cardiac outputmay have
prevented further desaturation. Nevertheless, in a recent
study the effect of the dual endothelin receptor antagonist
FIG. 2. Correlation between arterial O2 saturation and
maximal O2 uptake at 4559m. Control group, untreated
group; dexamethasone group, dexamethasone-treated
group; Vo2max, maximal O2 uptake expressed in percent of
value at low altitude; Spo2, arterial O2 saturation during
maximal exercise expressed in percent of value at low
altitude.
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bosentan on hypoxic Vo2max was investigated (Faoro et al.,
2009). It was demonstrated that bosentan signiﬁcantly lowers
pulmonary artery pressures and concomitantly improves
hypoxic Vo2max without affecting Spo2. Therefore, the con-
clusionwas drawn that right ventricular afterload reduction is
a key to improve exercise capacity at high altitude. Taken
together, these ﬁndings indicate that the cause or effect
question concerning increased cardiac output with improved
pulmonary O2 diffusion remains controversial and requires
further investigation with a reliable assessment of cardiac
output.
We also observed an increase in resting HR at 4559m only
in the control group, whereas in those participants receiving
dexamethasone, resting HR was similar to baseline values.
This is surprising, because acute exposure to hypoxia is nor-
mally accompanied by higher resting HR (Vogel and Harris,
1967). Nevertheless, a blunted HR after intake of dexameth-
asone in acute hypoxia has been reported previously andmay
be related to a modulation of increased sympathetic drive
(Maggiorini et al., 2006), which is a potential contributor to
increased pulmonary vascular resistance and pulmonary
capillary permeability (Duplain et al., 1999). However, in
agreement with earlier observations (Fischler et al., 2009),
acute hypoxia decreasedmaximal HR to a very similar degree
in both groups. Consequently, there is a larger difference be-
tween resting andmaximal HR; thus, an increasedHR reserve
in the dexamethasone groupmay have contributed to the gain
in maximal exercise capacity and supports the explanation
of right ventricular unloading in dexamethasone-treated
subjects.
It is important to note that dexamethasone might im-
prove exercise capacity even in normoxic conditions: high
dosages have been used in endurance sports on various
occasions to enhance performance (Arlettaz et al., 2006).
Therefore, the World Anti-Doping Agency (WADA) pro-
hibits administration of glucocorticosteroids during com-
petitions. This raises the question of whether our ﬁnding is
at all hypoxia related or just a consequence of a general
performance-enhancing effect of dexamethasone that is also
present in normoxic conditions. However, several studies
that have investigated the effect of dexamethasone on
normoxic exercise capacity found no improvement in sub-
maximal (Viru and Smirnova, 1982; Arlettaz et al., 2006;
Cordova Martinez, 2006; Arlettaz et al., 2008a) or maximal
(Marquet et al., 1999; Cordova Martinez, 2006; Arlettaz et
al., 2008b) exercise capacity, suggesting that the ameliora-
tion that dexamethasone brought to our subjects was in-
deed owing to a reduction of hypoxia-related impairment
of exercise tolerance.
Limitations
We tested our hypothesis by comparing a treatment group
to untreated subjects. The optimal design would have been a
crossover protocol in which each subject is its own control.
However, the obvious inconvenience for the subjects of
traveling to the Margherita hut twice argued against this de-
sign. Further, the scheduling of the second ascent would have
been problematic. A short interim would have allowed for an
altitude acclimatization carry-over. On the other hand, with a
long break, other factors, such as altered physical condition-
ing of the subjects, might have inﬂuenced the outcome of the
study.
Further, we included subjects of two separate studies
with differences in the treatment of our control subjects,
and so it may be argued that subjects receiving placebo
cannot be matched to untreated subjects. Since no differ-
ences were observed in hypoxic Vo2max between the 2007
and 2009 control groups and since both groups presented
with lower values than the dexamethasone group, we as-
sume that the fact that only a part of the control group
received placebo did not signiﬁcantly alter the outcome of
the study.
It is also true that the two experimental groups were not
equal with regard to gender distribution. We do not expect
this circumstance to bias our ﬁndings.Women can acclimatize
and perform at altitude as well as men (West et al., 2007), and
the menstrual cycle does not affect performance at high alti-
tude (Beidleman et al., 1999).
Since in our study we included only HAPE-s individuals,
we cannot transfer our ﬁndings to a general population.
However, assuming that subclinical HAPE is a common
phenomenon after climbing to Margherita hut within <24 h
(Cremona et al., 2002), it is possible that dexamethasonemight
have the same effect on individuals not susceptible to HAPE,
but this will have to be tested separately.
Conclusion
In conclusion, we found that a prophylactic administration
of 8mg dexamethasone b.i.d reduces the hypoxia-related
decline in Vo2max of HAPE-s subjects at 4559-m-high alti-
tude. This is most likely related to an increase in maximal
cardiac output and an improved pulmonary O2 diffusion,
both resulting in a higher convectional O2 transport to the
exercising muscles.
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Abstract 
Background: Subjects susceptible to the development of high altitude pulmonary edema 
(HAPE-s) experience an exaggerated rise in pulmonary artery pressure when exposed to acute 
hypoxia. As this may increase right ventricular afterload and/or impair transalveolar O2-
diffusion we hypothesized HAPE-s to experience a more pronounced impairment of maximal 
O2 uptake (VO2max) in hypoxia than normal individuals. 
 
Methods: 14 HAPE-s and 15 normal control subjects (Controls) performed baseline VO2max-
tests on a bicycle-ergometer at sea level. A few weeks later, the tests were repeated after a 
two-day ascent and an overnight stay at 4559 m altitude. Systolic pulmonary artery pressure 
(sPpa) was evaluated by trans-thoracic echocardiography at rest and at 20% and 30% of max-
imal exercise. 
 
Results: Exposure to 4559 m decreased VO2max by 33% ± 8% in Controls and by 39% ± 6% 
in HAPE-s (p=0.052 for group comparison). SpO2 during maximal exercise was 72% ± 10% 
and 74% ± 14%, respectively (p>0.05). Exercise elevated sPpa in both groups and at each 
altitude whereas no difference was observed between groups at sea level. However, at 4559 
m, resting sPpa was ~ 12 mmHg higher in HAPE-s than in Controls and this difference per-
sisted at both exercise intensities. 
 
Conclusion: The hypoxia-induced reduction in VO2max tended to be larger in HAPE-s than in 
normal individuals. Together with earlier studies that demonstrated an ergogenic effect of 
pharmacological pulmonary vasodilation in hypoxia this suggests that the pulmonary vaso-
constrictive response contributes to the exercise impairment at high altitude. 
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Introduction 
Maximal O2 uptake (VO2max) is reduced in acute hypoxia [1, 2] mainly due to two mecha-
nisms [3]: First, a decreased arterial PO2 (PaO2) induced by a lower alveolar PO2 and a result-
ing pulmonary diffusion limitation [2-4]. Second, a diminished maximal cardiac output due to 
a decrease in stroke volume and heart rate (HR) [3]. Both mechanisms contribute to a lower 
O2 delivery to the exercising muscles and hence a reduction in VO2max.  
This impairment may be even more pronounced in individuals prone to high altitude pulmo-
nary edema (HAPE). HAPE is a noncardiogenic edema, typically occurring after rapid ascent 
to altitudes > 2500 m [5]. In individuals susceptible to HAPE (HAPE-s), the mechanism of 
HAPE pathogenesis is an exaggerated vasoconstrictive response to alveolar hypoxia that leads 
to an excessive and inhomogeneous increase in pulmonary artery resistance [6]. This causes 
overperfusion of the remaining patent vessels and subsequent injury of capillary walls with 
leakage of red blood cells and proteins into the airways and alveoli [7]. 
It is obvious that an overt HAPE impairs exercise tolerance [6, 8]. Nevertheless, the excessive 
vasoconstrictive response of HAPE-s individuals might also reduce exercise capacity in the 
absence of a clinically significant pulmonary fluid accumulation. The developing pulmonary 
hypertension may increase right ventricular afterload, thus attenuating stroke volume [9], and 
deteriorate ventilation/perfusion matching [10]. Furthermore, even a subclinical extravascular 
fluid accumulation may elongate the distance for alveolar-capillary O2-diffusion and thereby 
amplify pulmonary diffusion limitation [11]. 
Accordingly, the current study was performed to test the hypothesis that acute exposure to 
hypoxia induces a larger reduction in VO2max in HAPE-s than in healthy control subjects 
(Controls). 
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Methods 
The present results were obtained in the years 2007 and 2009 at the Capanna Regina Mar-
gherita (4559 m), a high altitude research facility on Monte Rosa (Italy). 
The studies were performed with identical protocols at two occasions to allow inclusion of an 
appropriate subject number. They were approved by the Ethical Committee of the University 
of Zurich and conformed to the declaration of Helsinki. 
 
Subjects 
The investigation included both, HAPE-s (n=14) and Controls (n=15) as volunteers. All sub-
jects classified as HAPE-s had experienced at least on episode of HAPE in the past as con-
firmed in an interview by a physician with long experience in high altitude medicine. To pre-
vent bias from former altitude acclimatization, volunteers who spent more than five nights at 
an altitude higher than 2500 m within the last 30 days before the study were excluded. The 
anthropometric data of the participants is summarized in table 1. 
 
Table 1: Anthropometric data of the subjects 
 Controls HAPE-s 
Number of subjects 
Male 
Female 
15 
11 
4 
14 
9 
5 
Age (years) 41 ± 9 45 ± 9 
Height (cm) 174 ± 9 174 ± 8 
Weight (kg) 73 ± 11 70 ± 7 
BMI (kg/m2) 24 ± 2 23 ± 2 
HAPE-s= Subjects susceptible to high altitude pulmonary edema; BMI= Body mass index 
 
Protocol 
Baseline examinations were conducted at the University Hospital of Zurich (490 m, referred 
to as sea level), where subjects performed a VO2max test at least two hours after the last meal. 
Two to three weeks later, subjects traveled to Alagna (Italy, 1205 m), from where they were 
carried by cable car to an altitude of 2900 m. They continued by foot to the Gnifetti hut (3647 
m), where they arrived in the late afternoon and spent the night. During the course of the next 
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morning, they reached the Margherita hut (4559 m) after an additional 4 - 6 hours ascent. Af-
ter another overnight stay the second VO2max test was performed in the following morning. 
 
VO2max tests 
The VO2max tests were performed on an electronically braked bicycle ergometer in an up-
right position (Cyclus 2, RBM Elektronik, Leibzig, Germany). Subjects wore a face mask, 
covering mouth and nose for breath collection. Amperometric solid-state electrolyte sensors 
continuously measured O2- and CO2-concentration in the expired gas. Results were monitored 
and saved as breath-by-breath values on a portable computer. The utilized system (ZAN 600 
USB, nSpire Health, Louisville, USA) was calibrated before each test. HR was recorded by 
electrocardiogram (CardioCollect 12, Spacelabs Healthcare, Feucht, Germany) and peripheral 
arterial O2 saturation (SpO2) was measured by pulse oximetry (Masimo SET Radical, Inspira-
tion Medical, Bochum, Germany) on the earlobe. 
The trials started at a workload of 50 Watt which was then increased by 10 to 40 Watt per 
minute following a progressive ramp protocol individually tailored to lead to exhaustion with-
in 8 to 12 min [12]. At high altitude, the increments were thus chosen 30% lower than at sea 
level. During the last minutes of the test, subjects were vigorously encouraged to continue 
until exhaustion. 
 
Resting and exercise pulmonary artery pressures 
Systolic pulmonary artery pressure (sPpa) was evaluated at rest and during submaximal exer-
cise by trans-thoracic echocardiography, calculated from the pressure gradient across the tri-
cuspid valve using the modified Bernoulli equation and an estimated right atrial pressure of 
7mmHg [13]. However, due to technical problems, the measurements of 2007 were lost and 
thus our results contain only the sPpa values of the 8 HAPE-s and 15 Controls participating in 
2009. 
Resting sPpa was measured prior to the VO2max test with the subjects in the supine position. 
After the VO2max test, subjects rested for two hours. Subsequently, sPpa was measured with 
the subjects exercising in the semi-recumbent position on a table ergometer. Measurements 
were performed at two workloads that were set at 20% and 30% of the maximal workload 
achieved in the preceding VO2max test. sPpa was measured after 8 minutes at each workload 
and exercise was sustained during the procedure. 
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Data analysis and statistics 
Statistical data analysis was conducted using Sigmaplot 11.0. The effect of the exposure to 
high altitude within each group was evaluated by Wilcoxon matched pairs test. To compare 
the altitude induced changes between groups, the differences to the baseline results were ex-
pressed in percents and compared using student’s t-test. sPpA values at sea level and high 
altitude were compared by paired t-test and changes in sPpa with exercise intensity were test-
ed by ANOVA with Tukey post hoc test. Group differences in sPpa at a given altitude and 
exercise intensity were tested with student’s t-test. Results are given as mean ± SD. 
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Results 
Baseline testing at sea level 
Baseline examinations revealed that subjects were healthy, with normal pulmonary functions 
and free from signs of pulmonary hypertension. All of them were able to perform the exercise 
tests which revealed no differences between groups (Table 2).  
 
Testing at high altitude 
Exposure to altitude was well tolerated in both groups. Despite the ascent to 4559 m within 
less than 24 hours, no participant had to be treated for acute mountain sickness (AMS) or 
HAPE and all were able to perform the exercise trials. In both groups, hypoxia induced a sig-
nificant decrease in VO2max and maximal workload as well as in HR and SpO2 during maxi-
mal effort (Table 2). The altitude induced reduction in VO2max was 33 ± 8 % in Controls and 
39 ± 6 % in HAPE-s (p=0.052, Figure 1). Otherwise, the altitude-induced changes in all the 
measured variables were similar between the two groups. 
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Figure 1: The hypoxia-induced reduction in VO2max at 4559 m expressed in percentage of sea-level 
VO2max (p=0.052 for group comparison). HAPE-s= Subjects susceptible to high altitude pulmonary 
edema; VO2max= maximal O2 uptake. 
 
Pulmonary artery pressures 
Figure 3 illustrates sPpa at rest and during 20% and 30% of maximal exercise at both alti-
tudes. At each altitude Exercise increased sPpa in both groups. However, while no differences 
were present between the groups at sea level, sPpa at rest and both exercise intensities was 
~12 mmHg higher in the HAPE-s at high altitude. 
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Figure 2: Systolic pulmonary artery pressure (sPpa) at 490 m and 4559 m at rest and 20% and 30% of 
maximal exercise. *, p<0.05 vs. Controls; a, p<0.05 vs. rest at the same altitude; b, p<0.05 vs. values 
490m at the same intensity  
 
 
Table 2: Cardiopulmonary parameters at maximal exercise capacity 
 Zurich, 490m Margherita, Day 2, 4559m p-value for altitude effect 
Group Controls HAPE-s Controls HAPE-s Controls HAPE-s 
VO2max 
[L/min] 3.7 ±0.9 3.6 ± 0.7 2.4 ± 0.6 2.2 ± 0.4 <0.001 0.002 
VCO2 
[L/min] 4.2 ± 1 4.2 ± 0.8 2.7 ±0.7 2.4 ± 0.6 <0.001 0.002 
Wmax [W] 318 ± 73 279 ± 68 210 ± 64 178 ± 43 <0.001 0.002 
HR [1/min] 174 ± 9 179 ±8 162 ± 12 164 ± 12 <0.001 0.003 
VE [L/min] 
 131 ± 30 131 ± 23 134 ± 39 129 ± 29 0.50 0.75 
VE/VO2 36.0 ± 4.0 37.1 ± 5.2 55.0 ± 8.6 59.3 ± 8.0 <0.001 0.002 
VE/VCO2 31.1 ± 3.7 32.0 ± 4.2 49.8 ± 6.0 53.1 ± 7.1 <0.001 0.002 
F [1/min] 46 ± 7 46 ±5 50 ± 11 50 ± 10 0.36 0.06 
VT [L] 
 2.9 ± 0.6 2.9 ± 0.4 2.7 ± 0.65 2.6 ± 0.5 0.01 0.002 
F/VT 
[1/[L*min]] 16.6 ± 3.6 16.3 ± 3.6 19.6 ± 5.5 20.4 ± 6.4 0.01 0.005 
RER 1.16 ± 0.06 1.16 ± 0.04 1.10 ± 0.06 1.12 ± 0.07 0.01 0.08 
SpO2 
[%] 95 ± 3 96 ± 3 72 ± 10 74 ± 14 <0.001 0.002 
HAPE-s= Subjects susceptible to high altitude pulmonary edema; VO2max= maximal O2 uptake; VCO2= CO2 
output; Wmax= maximal workload; HR= heart rate; VE= minute ventilation; F= respiratory frequency; VT= tidal 
volume; RER= respiratory exchange ratio (VCO2/VO2); SpO2= arterial O2 Saturation. 
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Discussion 
The major finding of the present study was that the rapid ascent to 4559 m tended (p=0.052) 
to induce a larger decrease in VO2max in HAPE-s than in Control subjects which confirms 
our hypothesis. We further observed sPpa at altitude but not at sea level to be higher in 
HAPE-s than in Controls both at rest and during moderate exercise. 
The cardiovascular response to whole body exercise enhances sPpa even at sea level and in 
subjects that are not prone to the development of HAPE [14, 15]. As pulmonary vascular re-
sistance was shown not to rise but rather decline during normoxic exercise [16, 17], the in-
crease in sPpa with exercise was attributed to a higher pulmonary blood flow and an enhanced 
left atrial pressure [14]. In contrast to these findings in a general population, several studies 
focussed specifically on the exercise response of HAPE-s individuals at sea level [18-23]. In 
agreement with some [22, 23], but not all of these, the present study did not reveal a higher 
sPpa in HAPE-s during normoxic exercise. The contrast to some of the earlier studies [18-21] 
may be related to the exercise intensity since we measured sPpa during moderate exercise to 
assure appropriate echocardiographic quality. In contrast, previous studies that reported a 
higher sPpa in HAPE-s individuals [18-21] performed the measurements at more severe in-
tensities. Accordingly, the exercise stimulus in the present experiments may have been too 
mild to provoke differences between the two groups. This interpretation is supported by the 
findings of Grunig and co-workers [20] who measured sPpa at different workloads in individ-
uals with and without a history of HAPE and detected an elevated sPpa in HAPE-s only as the 
workload exceeded 40% of maximal exercise. 
In contrast to the results at sea level, sPpa at 4559 m was higher in HAPE-s than in Controls 
both at rest and during exercise. This is in agreement with earlier observations at the same 
altitude [13] and in different degrees of hypoxia [6, 21, 23]. The origin of this exaggerated 
increase in pulmonary artery pressure is still not entirely clarified, but it appears to be multi-
factorial as several mechanisms have been detected. An important factor seems to be a weak 
hypoxic ventilatory response which leads to a more marked decrease in alveolar PO2 and sub-
sequently reinforces the hypoxic pulmonary vasoconstriction [24-26]. Furthermore, an endo-
thelial dysfunction with high plasma levels of endothelin [27, 28] and low levels of NO in 
hypoxia has been reported [29]. Additional contributors may be a small lung volume with a 
low cross sectional area of the pulmonary vasculature for blood distribution [19] or an exces-
sive sympathetic activity, leading to increased pulmonary venous pressures [30]. 
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A limiting role of the elevated sPpa in hypoxia has previously been indicated in subjects with 
[31] or without history of HAPE [9, 32-34] by studies that pharmacologically induced pulmo-
nary vasodilatation by the phosophodiesterase-5-inhibitor Sildenafil [9, 33, 34], the glucocor-
ticoid Dexamethasone [31] or the dual endothelin receptor antagonist bosentan [32]. In these 
studies the ergogenic actions of the drugs were attributed to a reduced right ventricular after-
load [9, 32, 34] and a higher arterial oxygenation due to a lower alveolar fluid accumulation 
or an optimized ventilation/ perfusion matching [33, 34]. In agreement with these results the 
elevated sPpa in HAPE-s tended to impair VO2max in excess of the expected effect of high 
altitude in the present study. Nevertheless, the natural differences in sPpa between HAPE-s 
and Control subjects appear to have a minor impact as compared to the changes induced by 
pharmacological vasodilation. This may be related to a declining relative importance of such 
natural variations as incremental exercise progressively increased sPpa [14, 15] while the ab-
solute difference between the groups (~ 12 mmHg) remained unchanged (fig. 2). Indeed, the 
relative difference in sPpa between the groups was 34 % at rest, 26 % at the lower workload 
and 21 % at the higher workload, indicating a progressive decrease. In contrast, the relative 
importance of drug-induced reductions in sPpa appears to remain pronounced also at strenu-
ous intensities as indicated in a previous study [9], where even during maximal exercise the 
difference in sPpa between the Sildenafil- and the Placebo-group was 24 %. 
In summary, the present data suggest that the elevated sPpa in HAPE-s might affect VO2max 
but rather to a small extent, as long as no clinically overt HAPE develops. Since exercise in 
hypoxia seems to induce a similar rise in sPpa in individuals susceptible and resistant to 
HAPE the relative importance of natural differences may decline and be minor during strenu-
ous intensities as compared to pharmacologically induced changes. 
 
Acknowledgment 
This study was supported by the Zurich Center for integrative human physiology (ZIHP), the 
Hartmann-Muller foundation, the Olga-Meyenfisch foundation and the Dr. Ettore Crivelli 
foundation. 
 
32
References 
1. Calbet, J.A. and C. Lundby, Air to muscle O2 delivery during exercise at altitude. 
High Alt Med Biol, 2009. 10(2): p. 123-34. 
2. Wagner, P.D., New ideas on limitations to VO2max. Exerc Sport Sci Rev, 2000. 28(1): 
p. 10-4. 
3. Calbet, J.A., et al., Determinants of maximal oxygen uptake in severe acute hypoxia. 
Am J Physiol Regul Integr Comp Physiol, 2003. 284(2): p. R291-303. 
4. Lundby, C., et al., Maximal exercise and muscle oxygen extraction in acclimatizing 
lowlanders and high altitude natives. J Physiol, 2006. 573(Pt 2): p. 535-47. 
5. Bartsch, P., et al., High altitude pulmonary oedema. Swiss Med Wkly, 2003. 133(27-
28): p. 377-84. 
6. Basnyat, B. and D.R. Murdoch, High-altitude illness. Lancet, 2003. 361(9373): p. 
1967-74. 
7. Hultgren, H.N., High-altitude pulmonary edema: current concepts. Annu Rev Med, 
1996. 47: p. 267-84. 
8. Bartsch, P., High altitude pulmonary edema. Med Sci Sports Exerc, 1999. 31(1 
Suppl): p. S23-7. 
9. Ghofrani, H.A., et al., Sildenafil increased exercise capacity during hypoxia at low 
altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-
controlled crossover trial. Ann Intern Med, 2004. 141(3): p. 169-77. 
10. Podolsky, A., et al., Exercise-induced VA/Q inequality in subjects with prior high-
altitude pulmonary edema. J Appl Physiol, 1996. 81(2): p. 922-32. 
11. Steinacker, J.M., et al., Lung diffusing capacity and exercise in subjects with previous 
high altitude pulmonary oedema. Eur Respir J, 1998. 11(3): p. 643-50. 
12. ACCP, A., ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir 
Crit Care Med, 2003. 167(2): p. 211-77. 
13. Maggiorini, M., et al., High-altitude pulmonary edema is initially caused by an 
increase in capillary pressure. Circulation, 2001. 103(16): p. 2078-83. 
14. Bossone, E., et al., Range of tricuspid regurgitation velocity at rest and during 
exercise in normal adult men: implications for the diagnosis of pulmonary 
hypertension. J Am Coll Cardiol, 1999. 33(6): p. 1662-6. 
15. Bevegard, S., A. Holmgren, and B. Jonsson, Circulatory studies in well trained 
athletes at rest and during heavy exercise. With special reference to stroke volume and 
the influence of body position. Acta Physiol Scand, 1963. 57: p. 26-50. 
16. Wagner, P.D., et al., Pulmonary gas exchange in humans exercising at sea level and 
simulated altitude. J Appl Physiol, 1986. 61(1): p. 260-70. 
17. Groves, B.M., et al., Operation Everest II: elevated high-altitude pulmonary 
resistance unresponsive to oxygen. J Appl Physiol, 1987. 63(2): p. 521-30. 
18. Kawashima, A., et al., Hemodynamic responses to acute hypoxia, hypobaria, and 
exercise in subjects susceptible to high-altitude pulmonary edema. J Appl Physiol, 
1989. 67(5): p. 1982-9. 
33
19. Eldridge, M.W., et al., Pulmonary hemodynamic response to exercise in subjects with 
prior high-altitude pulmonary edema. J Appl Physiol, 1996. 81(2): p. 911-21. 
20. Grunig, E., et al., Stress Doppler echocardiography for identification of susceptibility 
to high altitude pulmonary edema. J Am Coll Cardiol, 2000. 35(4): p. 980-7. 
21. Dehnert, C., et al., Identification of individuals susceptible to high-altitude pulmonary 
oedema at low altitude. Eur Respir J, 2005. 25(3): p. 545-51. 
22. Viswanathan, R., et al., Pulmonary edema of high altitude. II. Clinical, 
aerohemodynamic, and biochemical studies in a group with history of pulmonary 
edema of high altitude. Am Rev Respir Dis, 1969. 100(3): p. 334-41. 
23. Hultgren, H.N., R.F. Grover, and L.H. Hartley, Abnormal circulatory responses to 
high altitude in subjects with a previous history of high-altitude pulmonary edema. 
Circulation, 1971. 44(5): p. 759-70. 
24. Hackett, P.H., et al., Abnormal control of ventilation in high-altitude pulmonary 
edema. J Appl Physiol, 1988. 64(3): p. 1268-72. 
25. Hohenhaus, E., et al., Ventilatory and pulmonary vascular response to hypoxia and 
susceptibility to high altitude pulmonary oedema. Eur Respir J, 1995. 8(11): p. 1825-
33. 
26. Matsuzawa, Y., et al., Blunted hypoxic ventilatory drive in subjects susceptible to 
high-altitude pulmonary edema. J Appl Physiol, 1989. 66(3): p. 1152-7. 
27. Sartori, C., et al., Exaggerated endothelin release in high-altitude pulmonary edema. 
Circulation, 1999. 99(20): p. 2665-8. 
28. Droma, Y., et al., Endothelin-1 and interleukin-8 in high altitude pulmonary oedema. 
Eur Respir J, 1996. 9(9): p. 1947-9. 
29. Busch, T., et al., Hypoxia decreases exhaled nitric oxide in mountaineers susceptible 
to high-altitude pulmonary edema. Am J Respir Crit Care Med, 2001. 163(2): p. 368-
73. 
30. Duplain, H., et al., Augmented sympathetic activation during short-term hypoxia and 
high-altitude exposure in subjects susceptible to high-altitude pulmonary edema. 
Circulation, 1999. 99(13): p. 1713-8. 
31. Fischler, M., et al., Dexamethasone but not tadalafil improves exercise capacity in 
adults prone to high-altitude pulmonary edema. Am J Respir Crit Care Med, 2009. 
180(4): p. 346-52. 
32. Faoro, V., et al., Bosentan decreases pulmonary vascular resistance and improves 
exercise capacity in acute hypoxia. Chest, 2009. 135(5): p. 1215-22. 
33. Faoro, V., et al., Effects of sildenafil on exercise capacity in hypoxic normal subjects. 
High Alt Med Biol, 2007. 8(2): p. 155-63. 
34. Richalet, J.P., et al., Sildenafil inhibits altitude-induced hypoxemia and pulmonary 
hypertension. Am J Respir Crit Care Med, 2005. 171(3): p. 275-81. 
 
 
34
 
 
Title 
Hypocapnia during hypoxic exercise and its impact on cerebral oxygenation, ventilation and maximal 
whole body O2 uptake 
 
Authors 
Christoph Siebenmann1,2*, Henrik Sørensen1,2*, Robert A. Jacobs1,3, Thomas Haider1,3, Peter 
Rasmussen1,2, Carsten Lundby1,2 
*The two authors contributed equally to the manuscript. 
 
Institutions  
1Zurich Centre for Integrative Human Physiology, 2Dept. of Physiology, University of Zurich, 
Switzerland, 3Vetsuisse, University of Zurich, Switzerland 
 
Running title 
Hypocapnia during hypoxic exercise 
 
Address for correspondence 
Carsten Lundby, Dept. of Physiol., Winterthurerstrasse 190, CH8057 Zürich, Switzerland. 
Carsten.lundby@access.uzh.ch 
 
In press at Respiratory Physiology and Neurobiology. 
 
 
35
 
 
Abstract 
With hypoxic exposure ventilation is elevated through the hypoxic ventilatory response. We tested the 
hypothesis that the resulting hypocapnia reduces maximal exercise capacity by decreasing i) cerebral 
blood flow and oxygenation and ii) the ventilatory drive. 
Eight subjects performed two incremental exercise tests at 3,454m altitude in a blinded manner. In one 
trial end-tidal PCO2 (PETCO2) was clamped to 40mmHg by CO2-supplementation. Mean blood flow 
velocity in the middle cerebral artery (MCAvmean) was determined by trans-cranial Doppler sonography 
and cerebral oxygenation by near infra-red spectroscopy. 
Without CO2-supplementation, PETCO2 decreased to 30±3mmHg (P<0.0001 vs isocapnic trial). 
Although CO2-supplementation increased MCAvmean by 17±14% (P<0.0001) and attenuated the 
decrease in cerebral oxygenation (-4.7±0.9% vs -5.4±0.9%; P=0.002) this did not affect maximal O2-
uptake. Clamping PETCO2 increased ventilation during submaximal but not during maximal exercise 
(P=0.99).  
We conclude that although hypocapnia promotes a decrease in MCAvmean and cerebral oxygenation, 
this does not limit maximal O2-uptake. Furthermore, hypocapnia does not restrict ventilation during 
maximal hypoxic exercise. 
 
Key words: Altitude, central fatigue, hypoxic ventilatory response, NIRS, respiratory muscle fatigue, 
ventilatory limitation 
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Introduction 
Hypoxia reduces maximal O2-uptake (?? O2max) by affecting each step of the O2 transport cascade 
(Calbet & Lundby, 2009). At the pulmonary level hypoxia decreases the pressure gradient across the 
alveolar-capillary membrane limiting diffusive O2 transport (Wagner et al., 1987). This becomes 
particularly critical during exercise as the elevated cardiac output shortens pulmonary capillary transit 
time (Hopkins et al., 1996). The alveolar-arterial PO2 difference widens with increasing intensities and 
the concomitant decrease in arterial O2 saturation (SaO2) eventually limits ?? O2max (Bebout et al., 1989; 
Calbet & Lundby, 2009). This is to some extent counteracted by the hypoxic ventilatory response 
which is activated by stimulation of the peripheral chemoreceptors and elevates pulmonary ventilation 
(??E) at rest and during exercise (Klausen et al., 1970; Lahiri et al., 1972). This partially restores 
alveolar PO2 and diffusive O2 transport (Calbet & Lundby, 2009). Concurrently, the hypoxic ventilatory 
response reduces arterial PCO2 (PaCO2) (Sutton et al., 1988) which further increases SaO2 by shifting the 
oxyhemoglobin dissociation curve to the left (Bohr et al., 1904). Despite this positive effect on 
oxygenation, however, hypoxic ventilatory response induced hypocapnia could negatively affect 
?? O2max by other mechanisms: 
First, hypocapnia may impair ?? O2max by a mechanism related to cerebral blood flow (CBF). Fatigue 
originating from the central nervous system is referred to as central fatigue and may be promoted by an 
insufficient O2 delivery to the brain (Amann & Calbet, 2008; Rasmussen et al., 2010). With exercise 
CBF generally increases up to intensities of 60-80% of maximal capacity where after it plateaus 
(Querido & Sheel, 2007) or decreases towards or below resting values (Moraine et al., 1993; Hellström 
et al., 1996). Since CBF is reduced in parallel with PaCO2 as arterial PO2 remains constant (Ide et al., 
2003), the reduction in CBF during exercise has been attributed to hypocapnia (Poulin et al., 2002; 
Rasmussen et al., 2006; Bhambhani et al., 2007). Accordingly, blunted CBF combined with low 
arterial O2-content in hypoxia causes brain de-oxygenation and may promote central fatigue (Imray et 
al., 2005; Rasmussen et al., 2006; Subudhi et al., 2009). This hypothesis was recently tested by 
Subudhi and co-workers (Subudhi et al., 2011) by providing inspiratory CO2 supplementation during 
exercise in hypobaric hypoxia corresponding to 4,875 m altitude. This intervention increased CBF and 
cerebral oxygenation but, contrary to their hypothesis, reduced maximal exercise capacity. We 
speculated that these intriguing findings might be explained by the severe degree of hypoxia that was 
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applied. There is indeed evidence that, for submaximal exercise, cerebral de-oxygenation only becomes 
a limiting factor when SaO2 falls below 82% (Amann & Calbet, 2008). However, maximal exercise 
capacity at altitudes > 4,000 m is crucially reduced by a decrease in maximal cardiac output (Calbet et 
al., 2003) and peripheral limitations (Lundby et al., 2008; Robach et al., 2008) which may together 
have overruled a potential benefit from an increased cerebral oxygenation. We therefore aimed to 
investigate whether the recent findings of Subudhi and colleagues (Subudhi et al., 2011) could be 
confirmed at an altitude that is < 4000 m, yet still in a range where effects of cerebral de-oxygenation 
on exercise performance have been observed previously (Goodall et al., 2012). 
A second mechanism by which hypocapnia may impair ?? O2max in hypoxia is attenuation of the 
ventilatory drive (Dempsey, 1976) as this effect could amplify the hypoxemia during maximal exercise. 
At sea level, inspiratory CO2 supplementation elevates maximal exercise ??E in young subjects (Babb, 
1997), suggesting an inhibitory effect of hypocapnia rather than a mechanical limitation. Since the 
mechanical constraints associated with ventilation may be reduced in hypobaric hypoxia (Mognoni et 
al., 1982) while at the same time hypocapnia is more pronounced (Sutton et al., 1988), we speculated 
the blunting effect of hypocapnia on ??E to persist or become more pronounced than at sea level. 
In summary, the aim of the present study was to investigate the impact of hypocapnia on exercise at 
3,454 m altitude. We hypothesized that clamping PETCO2 to 40 mmHg would increase i) CBF and 
cerebral oxygenation and ii) ??E during exercise. We further expected one of these mechanisms or a 
combination hereof to increase ?? O2max. 
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Methods 
Subjects 
Eight healthy subjects were recruited (5 males: 28±1 y, 77±10 kg, 182±5 cm, and 3 females: 27±1 yrs, 
47±5 kg, 163±5 cm). The study was conducted at the Jungfraujoch research station (3,454 m) in the 
Swiss Alps. It was approved by the local ethical committee (EK-2011-N-21) in accordance with the 
declaration of Helsinki. Prior to the start of the experiments, informed oral and written consents were 
obtained. 
 
Protocol 
Subjects were transported by train to the Jungfraujoch on the evening prior to the experiments and 
spent the night at the research station. The following day they performed two incremental exercise tests 
to exhaustion on an electronically braked bicycle ergometer (Monark 839E, Varberg, Sweden) 
breathing either ambient air (hypocapnic trial) or CO2-enriched air (isocapnic trial). In the latter the 
inspired CO2 fraction was continuously adjusted (Altitrainer, SMTEC, Nyon, Switzerland) to clamp 
PETCO2 at 40 mmHg. The order of the trials were randomized and subjects, but not the investigators, 
were blinded. The trials were separated by at least four hours where subjects had a snack and beverage. 
Both exercise trials followed the same protocol starting with a warm-up period of 10 min at 100 W 
(males) or at 80 W (females). Thereafter the workload was increased every minute by 25 or 20 W, 
respectively, until exhaustion. Verbal encouragement was given in the end of all trials. Maximal 
workloads completed in the exercise tests were calculated as Wmax= Wcompl + Wincrem × (t/60) with 
Wcompl being the last completed workload, Wincrem the workload increment per exercise step and t the 
number of seconds in the not completed workload. 
 
Cerebral blood flow and cerebral oxygenation 
The mean blood flow velocity in the middle cerebral artery (MCA vmean) was determined as an estimate 
of CBF by insonating through the temporal window by trans-cranial Doppler sonography (2MHz 
probe, Multi-Box, DWL, Singen, Germany; ST3 Digital, Spencer Technologies, Northbrough, USA). 
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This approach is based on the assumption that the diameter of the MCA does not change during the 
measurement which we did not confirm experimentally. However, since an influence of PaCO2 on the 
MCA diameter has previously been excluded (Serrador et al., 2000) we were confident that the changes 
observed in MCA vmean reflected those in CBF. After the lowest signal to noise ratio was obtained the 
insonation probe was fastened to a headband and secured with adhesive sonography gel. 
To assess cerebral oxygenation we used near infra-red spectroscopy (NIRS, NIRO-200, Hamamatsu, 
Japan), which exploits spatial resolution to attenuate the influence from superficial tissues. Although 
this technique is still affected by skin blood flow and cerebrospinal fluid (Yoshitani et al., 2007; 
Sørensen et al., 2012) it may detect changes in cerebral oxygenation during hypoxemia (Sørensen et 
al., 2012). We did not expect any differences between hemispheres, therefore the sensor was applied 
ipsilaterally to the Doppler probe. The sensor was placed high on the forehead to avoid influence from 
the frontal and saggital sinus. 
 
Ventilatory variables 
Subjects wore a mask covering nose and mouth for complete breath collection (Hans Rudolf, Kansas 
City, USA). The ventilatory exercise response was measured breath-by-breath by a spirometer 
(Cosmed Quark CPET, Rome, Italy). After the test, the highest average value for ?? O2 calculated over 30 
breaths was adopted as ?? O2max. PaCO2 was calculated from tidal volume and end-tidal PCO2 according to 
Jones et al. (Jones et al., 1979). A pulse oximeter (LifeSense, Nonin Medical Inc., Plymouth, USA) 
was applied to the subjects’ fingertip to determine SaO2 and heart rate (fH) was measured by a monitor 
belt (Polar Electro, Kempele, Finland). 
 
Statistical analysis  
Data were analyzed by two-way ANOVA on repeated measurements and given as mean with SEM. 
The statistical significance level was set to P < 0.05. The analysis was performed using SAS 9.2 (SAS 
Institute Inc., Cary, USA). 
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Results 
PETCO2 and PaCO2 
In the isocapnic trial PETCO2 was clamped to 40±1 mmHg throughout the whole test (Fig. 1a). In the 
hypocapnic trial PETCO2 decreased from 35±1 mmHg (P<0.0001 vs isocapnic trial) to 30±3 during 
maximal exercise (P<0.0001). Similarly, PaCO2 decreased in parallel with PETCO2 in the hypocapnic trial 
but remained close to 40 mmHg in the isocapnic trial (P<0.0001). 
 
Exercise capacity 
Clamping of PETCO2 had no effect on ?? O2max which was 3.3±1.0 l.min-1 in the hypocapnic and 3.2±1.0 
l.min-1 in the normocapnic trial (P=0.57). The ?? O2 response at different workloads is illustrated in Fig. 
1b. The maximal fH was 182±10 in the hypocapnic and 180±8 in the isocapnic trial, respectively 
(P=0.30). The corresponding maximally attained workloads were 243±68 W and 229±62 W (P=0.04). 
 
Cerebral blood flow and cerebral oxygenation 
In the hypocapnic trial MCA vmean increased with exercise (Fig. 2a) and reached a plateau 
approximately 20% above resting values (P<0.0001). In the isocapnic trial MCA vmean followed the 
same pattern but reached a higher plateau approximately 35% above resting values (P<0.0001). 
Furthermore, the exercise induced reduction in cerebral oxygenation was less pronounced in the 
isocapnic trial versus the hypocapnic trial (-5.4±0.9% vs. -4.7±0.9%; P=0.002, Fig. 2b). Individual data 
analysis revealed no correlation between changes in cerebral oxygenation and exercise capacity. 
 
Ventilatory variables 
Clamping PETCO2 tended to increase ?? E during submaximal exercise but this effect was abolished with 
increasing intensity (Fig. 1c). Similarly, PETO2 was elevated during the warm-up workload but 
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decreased to the levels observed in the hypocapnic trial with increasing exercise intensity (Fig. 1d). 
Other ventilatory variables during maximal exercise are summarized in Table 1. 
Pulse oximetry failed to provide a stable signal throughout the exercise trials. Accordingly, the SaO2 
response could not be analyzed. 
 
 
 
Figure 1: Ventilatory variables during incremental exercise at 3,454m with (isocapnia) or without (hypocapnia) 
CO2 added to the inspirate to maintain end-tidal PCO2 at ~40mmHg. Values are mean ± SEM for N=8. ??O2, 
pulmonary O2 uptake; ??E, pulmonary ventilation. 
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Figure 2: Middle cerebral artery mean velocity (A) and frontal lobe oxygenation (B) during incremental 
exercise at 3,454m with (isocapnia) or without (hypocapnia) CO2 added to the inspirate to maintain end-tidal 
PCO2 at ~40mmHg. Values are mean ± SEM for N=8. 
 
 
Table 1: Ventilatory variables during maximal exercise 
Hypocapnia Respiration frequency [breath.min-1] 50.8 ± 8.7 
 Tidal volume [l] 2.8 ± 0.9 
 Ventilation [l.min-1] 140 ± 42 
 Pulmonary ?? O2 [l.min-1] 3.3 ± 1.0 
 Pulmonary ?? CO2 [l.min-1] 3.8 ± 1.1 
 End-tidal PCO2 [mmHg] 29.6 ± 3.1 
 Calculated arterial PCO2 [mmHg] 31.5 ± 2.7 
Isocapnia Respiration frequency [breath.min-1] 47.7 ± 8.0 
 Tidal volume [l] 3.0 ± 0.9 
 Ventilation [l.min-1] 141 ± 46 
 Pulmonary ?? O2 [l.min-1] 3.1 ± 1.1 
 Pulmonary ?? CO2 [l.min-1] 3.5 ± 1.2 
 End-tidal PCO2 [mmHg] 39.3 ± 0.8 
 Calculated arterial PCO2 [mmHg] 40.3 ± 0.8 
 
Hypocapnia, control exercise; isocapnia, CO2 added to the inspirate to maintain end-tidal PCO2 at ~40mmHg. Values are 
mean ± SD for N=8. 
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Discussion 
We tested the hypothesis that hypocapnia during exercise at an altitude of 3,454 m promotes a 
decrease in cerebral oxygenation and blunts ?? E. We further speculated that these responses 
could contribute to the reduction in ?? O2max in hypoxia. In agreement with our hypothesis, 
clamping PETCO2 at 40 mmHg increased MCA vmean, as an estimate of CBF, and diminished 
the reduction in cerebral oxygenation. This, however, did not affect ?? O2max and argues against 
cerebral deoxygenation as an important limiting factor for incremental exercise in hypoxia. 
Furthermore, although the intervention tended to increase ?? E during submaximal workloads, 
this effect disappeared with increasing intensities, suggesting that other factors constrain ?? E 
during maximal exercise in hypoxia.  
 
Cerebral blood flow and cerebral oxygenation 
Central fatigue is defined as a decrease in neural motor drive despite a maintained or even 
increasing demand for muscle force generation (Gandevia et al., 1995). One proposed 
mechanism is that accumulation of fatigue-related metabolites in the contracting skeletal 
muscles increases the discharge rate in group III/IV afferents which, in turn, causes reflex 
inhibition of the α-motoneuron firing rate and thus limits further muscle contraction 
(Gandevia, 2001; Amann et al., 2007). Hypoxia promotes this process not only by 
accelerating the accumulation of fatigue-related muscle metabolites (Linnarsson et al., 1974) 
but also by increasing the resting firing rate of the III/IV afferents (Hill et al., 1992). Apart 
from this indirect pathway, hypoxia may also directly affect the central nervous system by 
depriving cerebral oxygenation (Amann & Calbet, 2008). Indirect support for this mechanism 
in humans is found in studies where subjects were switched to breathing a hyperoxic gas 
mixture immediately before exhausting in a hypoxic exercise test (Calbet et al., 2003; Amann 
et al., 2007; Subudhi et al., 2008). This restored cerebral oxygenation within seconds and 
enabled the subjects to continue exercising for several minutes. However, this approach is 
limited by the obvious global effect of hyperoxic breathing that restores oxygenation in all 
tissues. Accordingly, the isolated effect of the cerebral re-oxygenation could not be 
determined. To overcome this limitation Subudhi and co-workers manipulated cerebral 
oxygenation independent of SaO2 by increasing MCA vmean through inspiratory CO2 
supplementation (Subudhi et al., 2011). This intervention successfully elevated cerebral 
oxygenation but, contrary to their hypothesis, decreased maximal exercise capacity. We 
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speculated that the severe degree of hypoxia applied by Subudhi and colleagues, 
corresponding to 4,875 m, (Subudhi et al., 2011) induced cardiac (Calbet et al., 2003) and 
peripheral (Lundby et al., 2008; Robach et al., 2008) limitations to exercise that may have 
overruled a potential positive effect of the elevated cerebral oxygenation. Although there is 
evidence that, during submaximal exercise, cerebral hypoxia becomes a limiting factor only in 
severe hypoxia (Amann & Calbet, 2008), more recent studies observed an effect at an altitude 
that was similar to the one in the present experiments (Goodall et al., 2012) or even at sea 
level (Rasmussen et al., 2010). It should also be considered that incremental exercise, as 
applied in the present study, induces a progressive decrease in SaO2 (Hughes et al., 1968; 
Calbet et al., 2003) that eventually results in more pronounced hypoxemia than during 
submaximal exercise at the same altitude. Accordingly, we speculated that at the more 
moderate altitude of 3,454 m, where peripheral limitations are less pronounced and cardiac 
output is not curtailed, an increase in CBF and cerebral oxygenation may benefit maximal 
exercise capacity. Similar to the previous study (Subudhi et al., 2011), where MCA vmean 
tended (P<0.10) to be higher with CO2 clamping, MCA vmean in the present study increased 
starting from approximately 35% of maximal exercise. Despite this, and similar to the earlier 
observations (Subudhi et al., 2011), the associated increase in cerebral oxygenation did not 
lead to an increase in ?? O2max. These findings indicate that the diminished cerebral 
oxygenation during hypoxic exercise is not an important limiting factor for ?? O2max. However, 
it has to be considered that inspiratory CO2 supplementation may have induced restrictions to 
exercise that overruled a potential benefit of the elevated cerebral oxygenation. The 
intervention may have prevented a ventilatory compensation of the metabolic acidosis 
associated with heavy exercise (Wasserman, 1986). This could have impaired ?? O2max either 
by a direct influence on the exercising muscles (Sahlin, 1986) or indirectly by shifting the 
oxyhemoglobin curve to the right and thus decreasing SaO2 (Lundby et al., 2006). This is 
supported by the lower workloads reached in the isocapnic trial. Future studies could prevent 
this effect by maintaining arterial pH with bicarbonate supplementation. 
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Ventilation 
The major determinant of ?? O2max is convective O2 delivery to the exercising muscles 
(Wagner, 1996). In normally trained individuals the capacity of the pulmonary system is 
generally sufficient to prevent major O2 de-saturations (Bassett & Howley, 2000) and 
accordingly ?? O2max is primarily limited by the capacity to increase cardiac output (Ekblom & 
Hermansen, 1968; Coyle et al., 1984). Hypoxia, in contrast, reduces alveolar PO2 which 
attenuates the alveolar-capillary pressure gradient and thereby attenuates trans-alveolar O2 
diffusion. Consequently, SaO2 decreases gradually (Hughes et al., 1968; Calbet et al., 2003) 
secondary to an elevated cardiac output during exercise which shortens pulmonary capillary 
transit times (Hopkins et al., 1996). Since maximal cardiac output is unaffected in moderate 
hypoxia as compared to in normoxia (Stenberg et al., 1966; Hartley et al., 1973) each decline 
in SaO2 reduces convective O2 transport and thus ?? O2max (Calbet et al., 2003). Compensatory 
hyperpnoea counteracts this process by enhancing alveolar PO2 and partially restoring the 
driving pressure for diffusive O2 transport. Nonetheless, despite the hypoxic ventilatory 
response, ?? E remains insufficient to abolish the progressive hypoxemia during incremental 
exercise in hypoxia. This raises the question as to what prevents further elevations in ?? E 
despite an increasing hypoxic stimulation of the peripheral chemoreceptors. We speculated 
the hypocapnia that develops secondary to the hypoxic ventilatory response (Sutton et al., 
1988) to be a potential candidate. Hypocapnia is a potent antagonist to the ventilatory drive 
and has been reported to confine the hypoxic ventilatory response in resting humans (Huang 
et al., 1984; Steinback & Poulin, 2007). However, suppression of hypocapnia by inspiratory 
CO2 administration only tended to increase ?? E at submaximal workloads and was without 
effect during maximal exercise. This is in agreement with earlier observations in young 
amateur cyclists at a higher simulated altitude (Subudhi et al., 2011) and indicates that 
maximal ?? E in hypoxia is confined by other mechanism. An obvious candidate is the 
mechanical restriction associated with higher air flows (Guenette & Sheel, 2007). By applying 
inspiratory CO2 or Helium supplementation Babb (Babb, 1997) has previously demonstrated 
in the elderly, that mechanical restrictions may limit maximal exercise ?? E at sea level. In that 
study unloading of the airways by Helium increased maximal but not submaximal exercise 
VE. In contrast and similar to the present results CO2 supplementation only stimulated ?? E 
during submaximal workloads and had no effect during maximal exercise. A similar effect of 
airway unloading was recently observed in mild hypobaric hypoxia corresponding to 2,500 m 
altitude (Ogawa et al., 2010). Nevertheless, we hypothesized the effect of hypocapnia on ?? E 
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to dominate during exercise at higher altitude where the work of breathing may be reduced 
(Mognoni et al., 1982) while hypocapnia on the other hand is more pronounced. However, 
our results do not support this hypothesis and suggest that, at 3,454 m altitude, mechanical 
flow limitations may persist and prevent CO2 supplementation from increasing VE. This is 
further supported by the observation that ?? E during maximal exercise at altitude may match 
maximal voluntary ventilation (Forte et al., 1997). It has to be considered that the prediction 
of the highest attainable ?? E during exercise by a maximal voluntary ventilation manoeuvre is 
contentious since the voluntary breathing pattern differs from reflex ventilation (Jensen et al., 
1980) and the test outcome is depending on the duration of the manoeuvre (Kift & Williams, 
2008). Nevertheless, these confounding variables lead to an over- rather than underestimate of 
maximal exercise ?? E (Kift & Williams, 2008) and thus the absence of a ventilatory reserve at 
altitude (Forte et al., 1997) clearly suggests ventilatory limitation. 
Another mechanism that may have prevented the CO2 supplementation from increasing 
maximal ?? E is respiratory muscle fatigue. Previous work has demonstrated that the diaphragm 
and abdominal muscles are susceptible to fatigue during sustained high intensity exercise 
(Romer & Polkey, 2008). Generally, this is only observed when heavy exercise (>85% of 
?? O2max) is sustained for more than 8-10 minutes (Johnson et al., 1996) and not during 
incremental exercise tests (Romer et al., 2007). However, it should be considered that the 
development of respiratory muscle fatigue may be accelerated in hypoxia (Verges et al., 
2010) and we can thus not exclude a limiting role hereof in the present study although 
experimental support is at present lacking. 
In summary, the present results indicate that hypocapnia does not limit ?? E during maximal 
exercise in hypoxia and indicate a role of other mechanisms like mechanical limitation or 
potentially respiratory muscle fatigue. 
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Limitations 
In the present study we tested whether changes in cerebral oxygenation affect ?? O2max at 
altitude. Due to the design of our experiments, which included inspiratory CO2 
supplementation, we could not confirm the achievement of a true ?? O2max by standard criteria 
(ATS/ACCP, 2003). A clear plateau in the ??O2 response was reached in both trials by six 
subjects but not by the remaining two subjects. Nevertheless, since the maximal fH was 
similar between the two trials we are confident that the present results cannot be explained by 
insufficient subject effort during the isocapnic trial. A further limitation is that we assessed 
differences in CBF by measurements of MCA vmean. This approach is based on the assumption 
that the diameter of the insonated vessel was similar between trials. As indicated, a recent 
report excludes the influence of PaCO2on the arterial vessel diameter (Serrador et al., 2000). 
Furthermore, an increase in middle cerebral artery diameter in the isocapnic trial would have 
led to an under- rather than overestimation of CBF and thus our conclusions that the 
intervention increased CBF remains valid. It also has to be considered that the assessment of 
cerebral oxygenation by NIRS may be affected by changes in skin blood flow (Sørensen et 
al., 2012). We argue, however, that skin blood flow was likely similar between the two trials 
and thus cannot explain the difference in NIRS derived cerebral oxygenation. Finally, 
although our observations do not support the hypothesis that a decrease in cerebral 
oxygenation affects maximal exercise capacity in hypoxia we cannot rule out that this may 
have an effect on submaximal exercise performance. Future studies could investigate whether 
inspiratory CO2 supplementation increases time trial performance at altitude. 
 
Conclusion 
Although clamping of PETCO2 increased MCA vmean, as an estimate for CBF and augmented 
cerebral oxygenation this did not increase ?? O2max. Our results suggest that cerebral 
oxygenation is not a limiting factor for incremental exercise in hypoxia although it remains 
unknown whether acidosis due to CO2-supplementation overrode a potential effect. Our 
results further indicate that hypocapnia does not curtail ?? E during maximal exercise at 3,454m 
altitude. 
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The combination of living at altitude and training near sea level [live
high–train low (LHTL)] may improve performance of endurance
athletes. However, to date, no study can rule out a potential placebo
effect as at least part of the explanation, especially for performance
measures. With the use of a placebo-controlled, double-blinded de-
sign, we tested the hypothesis that LHTL-related improvements in
endurance performance are mediated through physiological mecha-
nisms and not through a placebo effect. Sixteen endurance cyclists
trained for 8 wk at low altitude (1,200 m). After a 2-wk lead-in
period, athletes spent 16 h/day for the following 4 wk in rooms ﬂushed
with either normal air (placebo group, n  6) or normobaric hypoxia,
corresponding to an altitude of 3,000 m (LHTL group, n  10).
Physiological investigations were performed twice during the lead-in
period, after 3 and 4 wk during the LHTL intervention, and again, 1
and 2 wk after the LHTL intervention. Questionnaires revealed that
subjects were unaware of group classiﬁcation. Weekly training effort
was similar between groups. Hb mass, maximal oxygen uptake (VO2)
in normoxia, and at a simulated altitude of 2,500 m and mean power
output in a simulated, 26.15-km time trial remained unchanged in both
groups throughout the study. Exercise economy (i.e., VO2 measured
at 200 W) did not change during the LHTL intervention and was never
signiﬁcantly different between groups. In conclusion, 4 wk of LHTL,
using 16 h/day of normobaric hypoxia, did not improve endurance
performance or any of the measured, associated physiological vari-
ables.
altitude; LHTL; performance; training
OVER THE PAST FIVE DECADES, endurance athletes have attempted
to improve sea-level performance by means of altitude train-
ing. In the early 1990s, Levine and Stray-Gundersen (36)
introduced the “live high–train low” (LHTL) strategy, where
athletes reside and spend the majority of the day at moderate
altitude while training closer to sea level. This paradigm aims
for athletes to beneﬁt from physiological adaptation to hyp-
oxia, while avoiding the detrimental impact of hypoxia on
high-intensity endurance training. After an initial study had
provided results indicating that LHTL enhances aerobic per-
formance in competitive runners (34), a bulk of follow-up
studies conﬁrmed these beneﬁts across a variety of endurance
disciplines (7, 50, 57, 59). None of them, however, used a
double-blinded design, and thus it cannot be ruled out that the
observed effects, especially on performance measures, were, at
least in part, mediated by a placebo effect (11, 56). Our main
aim with this study was therefore to investigate the effect of
LHTL in a double-blinded, placebo-controlled study.
A further aim was to examine the effect of LHTL on
exercise capacity in mild hypoxia. Some endurance disciplines,
such as cross-country skiing, frequently perform competitions
at moderate altitudes. However, even the mild hypoxia asso-
ciated with these altitudes may decrease maximal oxygen
uptake (VO2max) by reducing arterial O2 content (CaO2) (22,
43), and this mechanism seems to be particularly pronounced
in highly trained athletes (30, 31). It appears plausible that this
detrimental effect of moderate altitude could be counterbal-
anced by measures that enhance CaO2. Indeed, LHTL has
previously been reported to not only normalize but also evenly
enhance CaO2 at an altitude of 2,340 m so that VO2max was
partially recovered (55). However, the study was conducted
without a control/placebo group, and it thus remains unclear
whether the LHTL intervention was superior to conventional
training at low altitude. In the present study, we therefore
performed additional VO2max tests at a simulated altitude of
2,500 m to evaluate the impact of LHTL on exercise capacity
in mild hypoxia with a placebo-controlled study design.
There has been much controversy as to the mechanisms
underlying performance gains following LHTL (20, 35). In the
initial LHTL study and the follow-up studies by the same
group, performance gains were attributed to altitude-induced
polycythemia and a concomitant increase in convective O2
transport capacity (10, 34, 57). However, another subset of
LHTL studies failed to reproduce the erythropoietic stimula-
tion by LHTL and instead, observed improvements in exercise
economy following LHTL (19, 52, 53). In an attempt to shed
more light on the mechanisms underlying performance gains
with LHTL, we evaluated both total Hb mass (Hbmass) and
exercise economy on ﬁve occasions before, during, and after
the 4 wk of LHTL.
Thus the major aim of the present study was to determine
changes in endurance performance of highly trained endurance
athletes after 4 wk of LHTL (minimum 16 h/day at 3,000 m)
using a double-blinded, placebo-controlled design. The hy-
potheses to be tested were: 1) LHTL exerts a positive effect on
endurance performance (VO2max and time-trial performance),
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which is based on altitude-dependent physiological adaptations
and not exclusively on a placebo effect; 2) LHTL increases
VO2max at moderate altitude; and 3) potential performance
gains after LHTL correlate with changes in Hbmass.
METHODS
Subjects
Initially, 24 endurance athletes were recruited as subjects for the
present study. However, due to personal reasons, ﬁve subjects with-
drew participation in the last week before the study. Two further
subjects did not show up at the onset of the study for unknown
reasons. Finally, 17 highly trained endurance athletes living at or near
sea level (16 males, 1 female, age 29  6 years, height 179  8 cm,
body wt 69  9 kg) from various countries in North America and
Europe attended as subjects in the present study. All of them regularly
participated in endurance competitions on at least national levels in
disciplines related to cycling, i.e., road cycling, triathlon, cycle cross,
and/or mountain bike. To prevent bias from previous altitude accli-
matization, we excluded subjects who traveled to altitudes higher than
2,500 m within the last month before the study. All subjects gave
written, informed consent to participate, and the study was approved
by the local ethical boards (Kanton Zurich and Kanton Waadt,
Switzerland). During the course of the experiment, one subject de-
cided to withdraw participation for personal reasons, and hence, his
data were not included into the analysis. The remaining 16 subjects all
completed the study.
Study Design
At the onset of the study, subjects traveled to Prémanon, France
(1,135 m), where they lived for 8 full wk at the Centre National de Ski
Nordique, an accommodation of the French state, which is used by
national endurance athletes for housing and training. This facility is
equipped with fully furnished hypoxic rooms, in which athletes can
comfortably live while being exposed to adjustable normobaric hyp-
oxia. All of the experimental procedures of the study were performed
at the hospital La Vallée (Le Sentier, Switzerland), located at an
altitude of 1,020 m, 25 km away from Prémanon. Subjects were
transported from Prémanon to Le Sentier in mini-buses on experi-
mental days.
The ﬁrst 2 wk of the study served as a lead-in period, where
subjects were familiarized to the natural environment, and baseline
testing was performed. For the following 4 wk, the intervention
period, subjects were assigned to spend a minimum of 16 h/day in
one- to three-person hypoxic rooms containing either normobaric
normoxia (placebo group, n  6) or normobaric hypoxia (LHTL
group, n  10). The group classiﬁcation was performed in a stratiﬁed
but not randomized manner to provide optimal equality regarding
physiological parameters and regular distribution of athletes of dif-
ferent disciplines. Consequently, the LHTL group was composed of
three cross-cyclists, two triathletes, four road cyclists, and one moun-
tainbiker, and the placebo group of two cross-cyclists, one triathlete,
two road cyclists, and one mountain biker.
Three days prior to the study start, all rooms were controlled and
calibrated with precision gases by the company who built the facilities
(Fieldbrook, London, UK). Subjects were blinded toward the envi-
ronmental condition to which they were exposed in their rooms.
Furthermore, all investigators, except for the main investigator (who
did not perform any measurements), were blinded toward the group
assignment. All rooms had the required hypoxic equipment installed,
and the air pumps were constantly turned on. O2 fraction in each room
was continuously monitored from two independent O2 probes
(T7OX-V, Oxygen CiTiceL, City Technology, Portsmouth, UK) con-
nected to a control panel located in a room with restricted access. O2
fraction was controlled by the main investigator 5 days/wk (this
person staying in the control room overnight) and by a qualiﬁed
person from the center, not involved in any measurement, during the
2 other days. In addition, O2 fraction in each room was controlled
twice daily via a portable O2 sensor (Vandagraph VN2O2, Cambridge
Sensotec, Cambridge, UK) by either the main investigator or the
person from the center.
The LHTL group was exposed to a normobaric hypoxia equivalent
to 2,500 m for the ﬁrst 2 days/nights of the intervention period.
Thereafter, the O2 fraction was decreased, equivalent to 3,000 m. As
a result, morning arterial O2 saturation (SaO2), estimated by pulse
oximetry (NPB-290, Nellcor Puritan Bennett, Pleasanton, CA), was
92 2% in the LHTL group (at 3,000 m) and 97 1% in the placebo
group (P  0.05). Subjects were conﬁned to their rooms from 20:00
to 07:00, from 08:00 to 10:00, and again from 16:00 to 19:00 during
these 4 wk. However, they were always allowed to spend more time
in their rooms if desired (but this was not recorded). The conﬁnement
was rigorously supervised by the main investigator 5 days/wk and by
other investigators the remaining 2 days. For psychological reasons
and to blind the subjects regarding group classiﬁcation, all subjects
were assigned to different roommates and/or rooms on a weekly basis.
During the last 2 wk of the study, the postintervention period,
subjects were relieved of the room conﬁnement and hypoxic exposure.
These days had the purpose of monitoring how long potential effects
of LHTL would last. However, the blinding was maintained for both
subjects and investigators until the end of the study.
Five testing sessions were distributed over the 8 wk of the study.
They were scheduled in the ﬁrst 2 wk (BASELINE), after 3 wk in the
LHTL intervention (W 3), on the last 3 days of the LHTL intervention
(W 4), and 1 (W 1 POST) and 2 wk (W 2 POST) after termination of
the intervention period. To obtain a solid baseline value and allow for
test familiarization, all measurements (except for hypoxic VO2max; see
below in paragraph) were performed in duplicate during BASELINE,
each test separated from its previous by at least 4 days. For the
maximal exercise tests and the time trials, the better result of the two
tests was adopted as a baseline value, whereas for the measurement of
hematological parameters and cycling economy, the average value
over the two BASELINE tests was used. In the following four testing
sessions, all tests were performed only once, except during W 4,
where hematological parameters were again evaluated twice (with
calculation of the average value) and where hypoxic VO2max was not
tested. All other tests were performed once at this time point. The
protocol with the scheduling and content of the ﬁve testing sessions is
illustrated in Fig. 1.
Measurements
Hbmass. Hbmass was measured by a modiﬁed version of a carbon
monoxide (CO) rebreathing technique (41). The subject ﬁrst rested for
20 min in a semirecumbent position. Thereafter, 2 ml blood was
sampled from an antecubital vein through a 20-G catheter and ana-
lyzed immediately in quadruplicate for 1) percent carboxy-Hb
(%HbCO) and Hb concentration ([Hb]) on a hemoximeter (ABL800,
Radiometer, Copenhagen, Denmark) and 2) hematocrit by the micro-
method (4 min at 13,500 rpm). After baseline collection and control,
the subject ﬁrst breathed 100% O2 for 2 min to ﬂush nitrogen from the
airways. The breathing circuit (previously O2 ﬂushed) was then
closed, and a bolus (1.5 ml/kg) of 99.997% chemically pure CO (CO
N47, Air Liquide, Paris, France) was administrated and rebreathed for
8 min. At the end of the rebreathing period, another 2 ml blood sample
was obtained and analyzed, following the same procedure. The
change in %HbCO between ﬁrst and second measurement was used
for calculation of Hbmass, taking into account the amount of CO
remaining in the rebreathing circuit at the end of the procedure (2.2%)
(8). Total red blood cell volume (RCV), blood volume, and plasma
volume was derived from Hbmass, [Hb], and hematocrit (8). All CO
rebreathing tests were performed by the same operator. BASELINE
and W 4 values reported here correspond to the average of duplicate
measurements conducted on separate days within these testing ses-
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sions. The coefﬁcient of variation for Hbmass, assessed from duplicate
BASELINE during the lead-in period and expressed as the percent
typical error (i.e., SD of difference scores/2), was 2.6%.
Urine erythropoietin. Total urine erythropoietin (Epo) concentra-
tion was determined using an ELISA designed to target both endog-
enous and recombinant Epo isoforms (Quantikine IVD Epo ELISA,
R&D Systems, Minneapolis, MN). Morning urine (20 ml) was col-
lected (BD Falcon Tubes, BD Biosciences, Rockville, MD) under
visual inspection before breakfast and placed at80°C until analyzed.
Urine samples were collected on repeated occasions during the study.
Three time periods are reported here: 1) during the lead-in period
(BASELINE); 2) after 2–6 days of LHTL intervention; 3) after 20–27
days of LHTL. Subjects were fully informed that the purpose of urine
sampling was to screen for potential doping (no signs of recombinant
human Epo doping were found). Random collection explains why
urine samples were not collected on the same day for all subjects.
VO2max and cycling economy. VO2max was tested on an electron-
ically braked bicycle ergometer (Monark, Varberg, Sweden), and the
athletes used their own shoes and pedals and a race saddle. The
exercise protocol started with a warm-up period of 5 min at a
workload of 150 W, followed by 5 min at 200 W, except for the
female athlete, who warmed up at 100 and 150 W. Thereafter, the
workload was increased by 25 W/min1 until voluntary exhaustion.
During the last minutes of the test, subjects were vigorously encour-
aged to perform to complete exhaustion, and the achievement of
VO2max was established by standard criteria in all tests (1). Subjects
wore a face mask covering their mouth and nose for breath collection
(Hans Rudolph, Kansas City, MO), and O2 and carbon dioxide
concentration in the expired gas was continuously measured and
monitored as breath-by-breath values (Quark, Cosmed, Rome, Italy).
The gas analyzers and the ﬂowmeter of the applied spirometer were
calibrated prior to each test.
After the test, athletes recovered for 90 min, and then a second
VO2max test was performed, during which subjects were breathing a
hypoxic gas mixture corresponding to an altitude of 2,500 m (Alti-
Trainer, SMTEC, Nyon, Switzerland). This test followed the same
protocol as the previous, except that warm-up workloads were set at
100 W and 150 W (75 W and 125 W for the female athlete). A hy-
poxic trial was performed in each testing session, except during W 4.
After the test, breath-by-breath values were visually controlled and
averaged over 30 s. The highest average value was determined
VO2max, and all of the other parameters were picked at the same
time, except for maximal workload (Wmax), which was calculated as
Wmax  Wcompl  25 	 (t/60); Wcompl is the last completed
workload, and t is the number of seconds in the not-Wcompl.
To determine cycling economy, we assessed VO2 during submaxi-
mal steady-state cycling. For this purpose, the breath-by-breath values
of the last minute of the higher warm-up workloads (i.e., 200 W in
normoxia and 150 W in hypoxia) were averaged. Since the only
female athlete warmed up at lower workloads, she was not included
into the evaluation of cycling economy.
Arterial blood sampling. After local anesthesia with 2% lidocaine,
a 20-gauge catheter (model 80115.09R, Vygon Laboratories, Ecouen,
France) was inserted percutaneously using the Seldinger technique
into the radial artery. Arterial blood was sampled anaerobically in
heparinized syringes and analyzed immediately for [Hb], SaO2, and
lactate concentration by means of the ABL800. Arterial samples were
obtained during incremental exercise to exhaustion (VO2max) on two
separate occasions, i.e., at BASELINE and at W 3 during the nor-
moxic and hypoxic exercise trials. Samples were collected at 200 W
(normoxia) or 150 W (hypoxia) and at exhaustion. In the placebo
group, one subject did not undergo catheterization during W 3. In the
LHTL group, catheterization was not possible for one subject at
BASELINE and for two subjects at W 3. Arterial blood sampling was
thus conducted in n  5 (placebo) and n  7 (LHTL).
Time-trial performance. To evaluate exercise performance in a
scenario similar to competitions, subjects performed a time trial using
their own personal bike mounted on an electrically braked cycle
trainer (Fortius Virtual Reality Trainer, Tacx, Rotterdam, Nether-
lands). The combination with commercially available software al-
lowed for the simulation of a predeﬁned route on a portable computer.
We selected the ﬁnal section of the real Milan-San Remo race with a
length of 26.15 km. This route consists of a ﬁrst ﬂat part (4.8 km,
average incline 0.23%), a ﬁrst climb (5.5 km, 4.19%), a downhill part
(3.1 km, 6.79%), a second ﬂat part (8.6 km, 0.25%), and the ﬁnal
climb (4.15 km, 3.13%).
Athletes’ body weight was measured immediately before each trial
for software-based calculation of the appropriate resistance. After
warming up for a minimum of 10 min, athletes could rest again and
start the test whenever they felt ready. To achieve resemblance to
actual time-trial cycling competitions, subjects were free to manually
change gears and drink and eat ad libitum and allowed visual feedback
on the computer screen, which displayed their speed and covered
distance. To avoid potential inﬂuence from the pressure in the rear tire
on the recorded speed/time, the rear wheel of each bike was ﬁtted with
a power meter (Powertap Elite, CycleOps, Madison, WI), and
power output over the whole course was measured as outcome
variable. Subjects were vigorously encouraged during all tests.
Fig. 1. Study protocol and testing sessions.
The measurements performed in each testing
session are listed; (2) indicates that a measure-
ment was performed in duplicate within this
session. LHTL, live high–train low; Hbmass,
total Hb mass; VO2max, maximal oxygen up-
take; BASELINE, ﬁrst 2 wk; W 3, after 3 wk
in the LHTL intervention; W 4, on the last 3
days of the LHTL intervention; W 1 POST and
W 2 POST, 1 and 2 wk, respectively, after
termination of the intervention period.
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Personal Training and Monitoring
Subjects were instructed to follow their training habits and to keep
training intensity and volume as constant as possible throughout the 8
wk. Training was monitored using heart-rate monitors (Polar, Suunto,
or Garmin). The investigators advised some athletes on a few occa-
sions to either increase or decrease training volume and/or intensity.
Training monitoring did not include experimental exercise tests
(which were similar for all athletes) or training time spent at or below
55% of maximal heart rate. Furthermore, subjects frequently rode
back from the hospital to the housing facility after testing sessions,
and this training time (1 h on average, low to medium intensity) was
not recorded either. During weeks 3 and 4, subjects were asked to
reduce training the day before the exercise tests to minimize the
inﬂuence of fatigue.
Sport Nutrition and Iron Supplementation
During the entire study, subjects were provided ad libitum access to
commercially available energy drinks and carbohydrate and protein
bars (Sponser, Wollerau, Switzerland). The concentrations of ferritin
and soluble transferrin receptor (sTfR) were determined by immuno-
turbidimetric assay on a Hitachi 911 automatic analyzer (Boehringer,
Mannheim, Germany) in duplicates during the lead-in phase and
demonstrated that no subject was iron deﬁcient at the time of entering
the study; the mean value was 80.6  11.9 (range from 62 to 102)
ng/ml1 for ferritin and 2.5  0.3 (range from 2.0 to 3.1) mg/11 for
sTfR. To prevent any bias from iron deﬁciency, all subjects were
supplemented with a daily oral intake of 256 mg dried ferrous sulfate
(Tardyferon 80 mg, Pierre Fabre, Australia), starting upon arrival and
continuing until the end of the intervention period.
Efﬁcacy of the Blinding Process
The efﬁcacy of the blinding process was evaluated during the
intervention period by questionnaires in which subjects were repeat-
edly asked to state whether they believed to be living in normoxia or
hypoxia.
Statistics
Statistical evaluation of the data was performed by running a
two-way ANOVA with repeated measurements, combined with a
Tukey post hoc test for multiple comparisons. The statistical software
was the commercially available program SigmaPlot 5.0. The data are
presented as mean values  SD. A P value 0.05 was considered
statistically signiﬁcant. A maximum likelihood ANOVA determined
whether subject blinding was successful.
RESULTS
Training Effort and Efﬁcacy of the Blinding Procedure
Figure 2 illustrates training volume and intensity in both
groups. No difference in total exercise time or heart-rate
distribution was observed between the two groups at any point.
Although training intensity was well preserved, the recorded
training volume was decreased in both groups in the beginning
Fig. 2. Training. Training intensity (heart rate) and time (insets) over the course of the 8-wk study. In week-2 the volunteers arrived to the research facility, and
values only represent 4 days. Exercise effort during the experiments and subsequent bike rides back to the housing facilities are not accounted for in this ﬁgure
(as it can be assumed to be the same in both groups). Values for exercise intensity are weighted as means with SD and for the total training time, median with
25% quartiles. P and H with short lines indicate mean weighted heart-rate average for placebo and LHTL group, respectively. No differences were observed
across time and study group with respect to exercise intensity, whereas the measured total training time decreased signiﬁcantly with time in both groups but with
no difference between the 2 groups.
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and toward the end of the study. This was primarily related to
the high frequency of testing days in these weeks (exercise
tests and the subsequent bike ride from the hospital to the
facilities were not included into the monitoring of training
effort) and the tapering day before, on which subjects were
instructed to avoid long training sessions.
The results of the questionnaires evaluating the blinding
process are presented in Table 1. The large variation, with only
one-fourth of the subjects guessing right at the end of the
LHTL period (equal to the number of subjects guessing
wrong), indicates that the blinding process was successful, and
subjects were unaware of group classiﬁcation.
Hematological Parameters
Hematological parameters are summarized in Table 2 and
Fig. 3. Despite a higher reticulocyte count (P  0.05) in the
LHTL group (17.4  2.8%) than in the placebo group (12.7 
3.3%) at the end of the intervention period, Hbmass was not
affected and remained unchanged in both groups (Fig. 3, A and
B). Furthermore, neither [Hb] nor hematocrit revealed a statis-
tically signiﬁcant difference between the two groups. However,
during and after the LHTL intervention, both groups experi-
enced a marked hemoconcentration with a parallel decrease in
total blood volume and plasma volume and a concomitant
increase in [Hb] and hematocrit (Table 2).
At W 4—thus at the end of the LTHL intervention—an
increase in Hbmass, which exceeded the typical error of 2.6%
for the CO rebreathing procedure, was present in ﬁve of 10
subjects within the LHTL group, whereas in three subjects,
Hbmass had decreased by 
2.6% (Fig. 3C). The correspond-
ing individual changes in the placebo group are illustrated in
Fig. 3D.
No change in urine Epo was detected across time in the placebo
group, with values of 26.5  13.9 ng/l1 at BASELINE, 26.9 
14.3 ng/11 after 2–6 days, and 27.0  15.2 ng/l1 after 20–27
days of placebo exposure. In the LHTL group, urine Epo was
higher (P 0.05) after 2–6 days of LHTL exposure (35.7 26.8
ng/l1) than at BASELINE (20.8 15.5 ng/l1) but had returned
to levels similar to BASELINE after 20–27 days of LHTL
exposure (28.7 20.2 ng/l1). The relative increase in urine Epo
between BASELINE and short-term hypoxic exposure (days 2–6)
was found to be higher in the LHTL than in the placebo group
(P  0.05). However, absolute values at 2–6 days did not differ
signiﬁcantly between groups, and furthermore, there was no
correlation between hypoxia-induced changes in urine Epo and
the corresponding variations in either reticulocyte count or Hbmass
at any time point (results not shown).
Maximal Exercise Capacity
VO2max is illustrated in Fig. 4, and Table 3 summarizes
further cardiorespiratory parameters obtained during maximal
bicycle-ergometer exercise. The 8 wk of training increased
VO2max, expressed in ml/min1, by an average of 1.0 3.8%
in all subjects (P  0.06). However, VO2max remained unaf-
fected by the intervention in the LHTL group and did not differ
between groups at any time point. At W 4—thus at the end of
the LHTL intervention—VO2max was increased by 2.0 
1.6% in the placebo group and 0.0  2.8% in the LHTL group
(P  0.50 for factor “time”, and P  0.65 for interaction
between factors time and “group”). Correlation analysis indi-
cated that in both groups, individual changes in VO2max were
not correlated to changes in either Hbmass or [Hb].
Similar to the normoxic trials, VO2max in hypoxia remained
unaffected by the intervention (Fig. 4C) in both groups.
Arterial Blood Parameters During Exercise
Arterial blood parameters are summarized in Table 4, A
(normoxic exercise) and B (hypoxic exercise at 2,500 m). The
main result is that in both environmental conditions, 3 wk of
LHTL exposure induced an increase in arterial [Hb], which
supports the hemoconcentration observed in venous blood
during CO rebreathing.
Cycling Economy
Cycling economy, expressed as average VO2 during the
higher warm-up workloads in normoxia (200 W) and hypoxia
(150 W), is presented in Fig. 5. During the normoxic trials at
W 1 Post (Fig. 5A), cycling economy at 200 W was decreased
Table 1. Efﬁcacy of subject blinding
Days of LHTL Guessed right Guessed wrong Could not decide
4 8 (50%) 3 (19%) 5 (31%)
8 7 (44%) 6 (38%) 3 (19%)
11 5 (31%) 4 (25%) 7 (44%)
18 7 (44%) 6 (38%) 3 (19%)
25 8 (50%) 4 (25%) 4 (25%)
28 4 (25%) 4 (25%) 8 (50%)
Number and fraction of subjects, able or unable to determine whether
exposed to hypoxia or not. Time effect was not signiﬁcant (P  0.639).
“Guessed wrong” and “Could not decide” answers were pooled. The maximal
likelihood for the subjects to guess right was P  0.30. The maximal
likelihood for them to guess wrong or could not decide was P  0.06. LHTL,
live high–train low.
Table 2. [Hb], hematocrit, and intravascular volumes evaluated by carbon monoxide rebreathing
Placebo group (n  6) LHTL group (n  10)
BASELINE W 3 W 4 W 1 POST W 2 POST BASELINE W 3 W 4 W 1 POST W 2 POST
[Hb] (g/dl) 14.1 0.3 15.2  0.6* 15.3  0.6* 15.0  0.6* 15.1  0.6* 13.9  0.6 15.8  0.6* 15.1  0.7* 14.9  0.7* 15.1  0.7*
Hct (%) 43.0 0.7 46.8  1.6* 47.0  1.4* 46.0  1.5* 46.5  1.3* 42.4  1.8 47.8  2.3* 46.4  2.0* 45.5  2.0* 46.2  2.2*
RCV (l) 3.00 0.33 3.01  0.27 3.00  0.28 3.00  0.34 3.01  0.30 2.84  0.50 2.80  0.50 2.89  0.52 2.73  0.50 2.76  0.47
PV (l) 3.98 0.37 3.43  0.38* 3.39  0.38* 3.49  0.46* 3.47  0.38* 3.86  0.67 3.05  0.44* 3.33  0.57* 3.26  0.54* 3.21  0.52*
BV (l) 6.97 0.70 6.44  0.61* 6.38  0.64* 6.45  0.77* 6.49  0.66* 6.69  1.14 5.84  0.91* 6.21  1.05* 5.99 1.00* 5.97  1.00*
[Hb], venous Hb concentration; Hct, hematocrit; RCV, total red blood cell volume; PV, blood plasma volume; BV, total blood volume; BASELINE, ﬁrst 2
wk; W 3, after 3 wk in the LHTL intervention; W 4, on the last 3 days of the LHTL intervention; W 1 POST and W 2 POST, 1 and 2 wk, respectively, after
termination of the intervention period. Values are means  SD; *P  0.05 versus BASELINE; no signiﬁcant differences between groups were observed.
57
by 6.9% in all subjects (P 0.05). However, the economy was
never signiﬁcantly different between the two groups. Economy
evaluated during the hypoxic trials was unchanged throughout
the entire study in both groups and never differed between
groups (Fig. 5B).
Time-Trial Performance
Average power output during the 26.15-km time trial, ex-
pressed in Watt, is illustrated in Fig. 6. We observed a constant
trend toward an increase in time-trial performance in all of our
subjects over the course of the 8 wk, averaging 5% at the end
of the study (P  0.12). However, there was no effect of the
LHTL intervention, and thus time-trial performance was al-
ways similar between the two groups. Separate analysis of ﬁve
speciﬁc segments of the time trial (including climbs, descents,
and ﬂat sections) revealed no difference between groups either.
At the end of the intervention period, i.e., at W 4, time-trial
performance was increased by 5% in the placebo group and by
2% in the LHTL group (P 0.12 for factor time, and P 0.33
for interaction between factors time and group).
DISCUSSION
In the present study, we applied a double-blinded and
placebo-controlled design to investigate the effects of LHTL
on endurance performance of highly trained endurance cy-
clists. Our main ﬁnding is that LHTL did not affect Hbmass,
26-km time-trial performance, VO2max, or exercise economy
in normoxia and moderate normobaric hypoxia, indicating that
4 wk of LHTL, using normobaric hypoxia, may not be superior
to conventional endurance training.
Impact of LHTL on Aerobic Performance
Our ﬁndings are in contrast to the results of the initial LHTL
study (34) and several follow-up studies, where improvements
in VO2max (7, 16, 50, 57) or endurance performance (57, 59)
have been reported. This is intriguing, since we designed the
LHTL intervention according to generally accepted recommen-
dations, which for simulated altitude, range from 4 wk at
2,500–3,000 m (12–16 h/day) (61) to 18 days at 2,500 m (12
h/day) (44). Our total hypoxic dose exceeded 440 h at 2,500–
3,000 m and was among the highest compared with studies
Fig. 3. Hbmass. A and B: individual values for Hbmass in the LHTL and placebo groups, respectively. Values at BASELINE and W 4 are average values of duplicate
measurements. Group average values are represented by the triangles. Individual changes in Hbmass from BASELINE to W 4 (i.e., the end of the intervention
period) are depicted in C for the LHTL group and D for the placebo group. The dashed lines represent the typical error of the carbon monoxide rebreathing
procedure in the present study (2.6%).
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conducted in the past (7, 19, 33, 34, 44, 48–50, 52, 53, 58, 59,
61). Together with the strict control of the administrated
atmosphere in the two groups, lower-pulse SaO2 conﬁrms
hypoxemia in our subjects, whereas the elevated urine Epo
levels and higher reticulocyte counts in the LHTL group
suggest an accordingly physiological response. It is therefore
unlikely that our results were associated with an insufﬁcient
hypoxic stimulus in the LHTL group. Furthermore, daily oral
iron supplementation was provided, and the intake was con-
trolled to avoid iron insufﬁciency. Finally, training intensity
was well preserved in all groups over the course of the study,
and the slight (nonsigniﬁcant) increase in VO2max and time-
trial performance in our already highly trained subjects indi-
cates that the training stimulus was adequate. This raises the
question as to why the LHTL group did not beneﬁt from the 4
wk of the intervention. In this context, it is important to note
that in the present study, the intervention failed to reproduce
the physiological adaptations that have previously been pro-
posed to underlie performance gains following LHTL, and
accordingly, the lack of an ergogenic impact appears as a
logical consequence. The absence of physiological adaptations
to hypoxia in the LHTL group is discussed further below.
With the assessment of measures for aerobic performance
using a double-blinded design, we had speculated to dem-
onstrate that the ergogenic impacts of LHTL are indepen-
dent of a placebo effect. Since earlier LHTL studies were
always conducted with an unblinded design, it cannot be
ruled out that a placebo effect may at least in part be
responsible for the performance gains. This limitation may
be particularly crucial in LHTL studies where the expected
effects are minor (20). In fact, a recent meta analysis of 51
LHTL studies reported that the potential performance gains
in elite athletes is 4% (5). It is important to note in this
context that with this large number of studies, the design and
the quality are subject to great variation, which may have
affected the outcome of the meta analysis. It nevertheless
remains intriguing that an earlier study investigating the
inﬂuence of a placebo effect on time-trial performance of
competitive cyclists observed improvements that were in the
same range as reported in the meta analysis (11). Further-
more, an open-label study design, as has been used in all
previous LHTL studies, may not only have led to perfor-
mance gains in the intervention group but may also have
hampered the control group by a “nocebo effect” (3), i.e.,
the detrimental impact of low expectations and demotiva-
tion. This may have further widened the gap between
subjects of the control and the intervention groups and
ultimately created a statistically signiﬁcant difference in
some studies. To overcome this limitation, the present study
was performed with a placebo-controlled design, and as
illustrated in Table 1, our strategy to blind the subjects was
successful. Nevertheless, since in our study, LHTL failed to
improve aerobic performance, the present results cannot
exclude that the performance beneﬁts of LHTL reported in
the past were, at least in part, related to a placebo effect. It
could be retorted that if LHTL would beneﬁt athletes by a
placebo effect, our placebo group should have improved
performance. Nevertheless, our subjects were always uncer-
tain about their respective group classiﬁcation, which may
have prevented a potential placebo effect, as it may occur in
open-label studies.
In summary, our study provides no indication for LHTL,
using normobaric hypoxia, to improve time-trial performance
or VO2max of highly trained endurance cyclists more than
conventional training. Given the considerable ﬁnancial and
Fig. 4. VO2max in normoxia (A and B) and normobaric hypoxia (C). A and
B: in the normoxic tests (individual results for the LHTL group and the placebo
group), the BASELINE values represent the better results of the duplicate
measurement performed. Group average values are represented by the triangles
in both ﬁgures. C: in the hypoxic tests, the columns represent mean values in
both groups, and SDs are indicated by error bars. No signiﬁcant changes or
differences between groups were observed in either condition.
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logistic effort of performing a LHTL camp, this should be
taken into consideration before recommending LHTL to elite
endurance athletes.
Potential Mechanisms Underlying LHTL
In their initial LHTL study, Levine and Stray-Gundersen
(34) related the aerobic improvements following LHTL to a
8% gain in RCV, which correlated (r  0.37; P  0.02) to
the increase in VO2max. They hence concluded that the
mechanism underlying LHTL is an enhanced, convective O2
transport capacity, secondary to erythropoiesis stimulated
by hypoxia. This approach seems convincing, since convec-
tive O2 transport is the primary limiting factor of VO2max
(32, 51) and because acute manipulations of blood O2
carrying capacity entail changes in VO2max accordingly
(14, 18, 40). Nevertheless, although the hypoxic exposure in
the present study conformed with the generally accepted
recommendations (44, 61) and despite quantifying Hbmass
on ﬁve different occasions with duplicate measurements
during BASELINE and 4 W, we failed to detect an increase
in Hbmass in the LHTL group. In both groups, however, we
observed some individuals to increase or decrease Hbmass by
the 
2.6% typical error associated to our measurement, but
these were all in a range that can be explained by natural
variations over time (42). Accordingly, the increase in [Hb]
in both groups was not caused by erythropoiesis but by a
reduction in plasma volume. The latter may have counter-
acted a potential ergogenic effect of a higher O2 carrying
capacity secondary to the enhanced [Hb] (27). This expla-
nation is supported by the fact that individual changes in
[Hb] were not correlated to changes in VO2max.
The intriguing observation that Hbmass remained unaffected
raises the question as to why the hypoxic stimulus failed to
reproduce a erythropoietic response similar to that observed by
Levine and Stray-Gundersen (34). Since Hbmass appears insen-
sitive to a placebo effect, this ﬁnding cannot be explained by
the applied study design, and accordingly, other explanations
should be considered.
In the initial LHTL study (34), subjects lived at natural
altitude, as opposed to the artiﬁcially created normobaric
hypoxia used in the present study, and it is tempting to
conclude that this might explain the different outcomes of
the two studies. Since performing a LHTL camp at natural
altitude is related to a considerable logistic effort and due to
the geographical conditions not feasible in many countries,
the use of normobaric hypoxia is an appealing alternative
for athletes. However, this is based on the assumption that
the response to altitude is solely dependent on O2 partial
pressure and unrelated to barometric pressure. This has been
questioned recently (12), and several studies have reported
slight differences between the effects of normobaric and
hypobaric hypoxia (37, 46, 54). Most importantly, in the
present context, the reduction in CaO2 seems to be more
marked in hypobaric than in equivalent normobaric hypoxia
(54). For this reason, the recommended minimal “altitude”
Table 4B. Arterial blood parameters during exercise in
acute normobaric hypoxia (2,500 m)
Placebo group (n  5) LHTL group (n  7)
BASELINE W 3 BASELINE W 3
SaO2 (%)
150 W 88.3  2.9 88.4  1.9 86.9  3.9 89.7  4.2
Exhaustion 86.7  5.0 83.2  5.3 79.5  4.8* 84.5  5.2†
[Hb]art (g/dl)
150 W 14.9  0.6 14.9  0.9 14.1  0.6 15.5  0.8†
Exhaustion 15.8  0.5 16.2  0.7 15.0  0.6 16.3  0.9†
[La]art (mmol/l)
150 W 1.2  0.5 1.4  0.4 1.5  0.6 1.7  0.4
Exhaustion 16.2  3.6 15.2  3.4 17.5  2.4 14.3  2.7
pHart
150 W 7.45  0.02 7.42  0.05 7.46  0.02 7.42  0.08
Exhaustion 7.27  0.07 7.20  0.13 7.27  0.05 7.28  0.08
Values are means  SD; *P  0.05 versus BASELINE; †P  0.05 versus
placebo.
Table 3. Workload and respiratory parameters during maximal cycling exercise
Placebo group (n  6) LHTL group (n  10)
BASELINE W 3 W 4 W 1 POST W 2 POST BASELINE W 3 W 4 W 1 POST W 2 POST
Workload (W) 411  23 412  31 422  28 418  30 417  33 405  59 400  62 413  57 398  56 405  55
VCO2 (l/min) 5.35  0.46 5.25  0.45 5.59  0.57 5.37  0.51 5.39  0.66 5.30  0.75 5.01  0.74* 5.25  0.74 5.19  0.84 5.30  0.73
VE/VO2 37.3  2.7 37.0  2.2 36.6  2.9 36.6  2.0 37.7  1.7 37.3  4.0 37.8  3.0 38.7  3.3 36.7  2.5 36.7  2.8
VE /VCO2 34.4  2.3 34.2  1.1 33.1  3.1 34.2  1.8 34.4  1.4 33.4  3.8 35.1  3.2 35.0  3.4 33.7  2.7 33.3  2.9
RER 1.08  0.04 1.08  0.04 1.11  0.02 1.07  0.03 1.09  0.03 1.12  0.04 1.08  0.04* 1.11  0.06 1.08  0.07 1.10  0.06
VE (l/min) 187  5 183  13 188  15 187  15 188  19 181  35 180  33 187  32 180  34 180  27
F (min1) 60  8 59  8 59  5 58 9 60 4 58 7 54 6 58 7 53 4 54 5
VCO2, carbon dioxide (CO2) output; VO2, oxygen (O2) uptake; VE, minute ventilation; RER, respiratory exchange ratio (VCO2/VO2); F, respiratory frequency.
Values are means  SD; *P  0.05 versus BASELINE; no signiﬁcant differences between groups were observed.
Table 4A. Arterial blood parameters during exercise in
normoxia
Placebo group (n  5) LHTL group (n  7)
BASELINE W 3 BASELINE W 3
SaO2 (%)
200 W 95.3  1.2 94.5  1.7* 93.8  3.1 94.5  2.6*
Exhaustion 92.5  4.0 91.7  3.4 88.7  2.2 91.4  2.68*
[Hb]art (g/dl)
200 W 14.9  0.4 15.2  0.5 14.2  0.6 15.5  1.0*
Exhaustion 15.6  0.7 16.3  0.7 15.2  0.5 16.7  1.0*
[La]art (mmol/l)
200 W 1.4  0.5 1.6  0.6 1.9  0.9 1.7  0.5
Exhaustion 17.4  1.7 15.7  2.7 18.7  2.1 16.2  3.8
pHart
200 W 7.43  0.02 7.41  0.02 7.42  0.03 7.39  0.07
Exhaustion 7.22  0.03 7.22  0.06 7.22  0.05 7.20  0.06
SaO2, arterial O2 saturation; [Hb]art, arterial [Hb]; [La]art, arterial lactate
concentration; pHart, arterial pH. Values are means  SD; *P  0.05 versus
BASELINE.
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for LHTL is also higher for normobaric hypoxia than for
hypobaric hypoxia (44, 61), and this was taken into account
in the present study. It should also be recognized that a
previous study, conducted in the very same facilities, ap-
plied an equal degree of normobaric hypoxia and observed
a pronounced increase in Hbmass in the intervention group
(7). We therefore conclude that neither the form nor the
degree of hypoxia applied in the present study can explain
the absence of a erythropoietic impact in the LHTL group.
A further potential explanation may be the loss of plasma
volume, which was observed in both groups and accordingly,
not a response to hypoxic exposure per se. Although the
increase in urinal Epo concentration in the LHTL group speaks
against it, the resulting hemoconcentration might have sup-
pressed Epo synthesis and therefore, counteracted a potential
erythropoietic stimulus in the LHTL group (4). We can indeed
not explain the observed hemoconcentration, but it might have
been a consequence of using normobaric hypoxia, which re-
quired our subjects to reside inside the hypoxic rooms for a
considerable part of the day and thus limited their involvement
in regular daily activities. It may be argued that these unusually
long periods of inactivity might have triggered a reaction
similar to that observed during bed-rest conﬁnement, where a
loss of plasma volume has been reported (23). Since the impact
of room conﬁnement in elite athletes remains uncertain, a
potential effect on the plasma volume contraction in our
subjects cannot be excluded, although the observation that
plasma volume did not normalize after the end of the interven-
tion period argues against it.
Although the absence of an increase in Hbmass in our study
was unexpected, it is partially supported by a retrospective
analysis of the original data of Levine and Stray-Gundersen
and coworker (10), where an increase in RCV was observed
only in those subjects who also experienced an increase in
endurance performance, which corresponded to 55%. This
indicates a considerable interindividual variation in the re-
sponse to LHTL, which is supported further by other studies
reporting that the increase in serum Epo during prolonged
Fig. 5. Exercise economy during submaximal cycling in normoxia (A) and normobaric hypoxia (B). Economy in both conditions was evaluated as VO2, averaged
over the last minute of the higher warm-up workload (i.e., 150 W in hypoxia and 200 W in normoxia). The columns represent mean values in both groups, and
SDs are indicated by error bars. The normoxic BASELINE values represent the average of the duplicate measurement performed. At W 1 POST, economy was
slightly decreased in both groups compared with BASELINE (as indicated by *), but no signiﬁcant differences between groups were observed.
Fig. 6. Time-trial performance is expressed as mean power output over a 26.15-km-simulated time trial. Individual results of the subjects in the LHTL group
(A) and the placebo group (B) are presented. The BASELINE values represent the better results of the duplicate measurement performed. Group average values
are represented by the triangles in both ﬁgures. No signiﬁcant changes or differences between groups were observed over the course of the study.
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exposure to high altitude is variable by a factor 
40 between
individuals chronically exposed to very high altitude (45) or
from 41 to 400% in subjects acutely exposed to moderate
hypoxia (17). It thus appears that in LHTL studies, the pres-
ence of an effect on Hbmass crucially depends on the random
composition of the subject groups. This may, in combination
with differences in study design, be the reason for the various
outcomes of previous LHTL studies regarding gains in Hbmass/
RCV and perhaps also explain the lack of an increase in Hbmass
in the present study. In this context, it could be considered
whether the already high BASELINE Hbmass in our subjects
could have contributed to our negative ﬁndings. Indeed, the
BASELINE values for Hbmass and RCV in our subjects were
considerably higher than those reported in previous LHTL
studies, demonstrating the most marked erythropoietic effects
(7, 34, 59). The high Hbmass may have blunted a potential
erythropoietic response compared with less-trained subjects
with accordingly lower Hbmass. This, however, needs further
research to be conﬁrmed.
In summary, while the results of some earlier studies (7, 34,
53, 57, 59) indicate that LHTL may stimulate erythropoiesis in
some athletes, our results demonstrate that this response is not
certain in all subjects, which is probably explained by different
individual responses to hypoxia (25). Coaches and athletes
should be aware of this issue and remember that an individual’s
erythropoietic response to LHTL is, to date, difﬁcult to predict.
The other common explanation for LHTL to increase per-
formance is related to skeletal muscle adaptations to hypoxia
(20). Gore and coworkers (19, 52, 53) base this on the obser-
vation of a higher exercise economy or muscle-buffer capacity
(19) following LHTL. Exercise economy is, next to VO2max
and the percentage of VO2max at which exercise is performed,
one of the main components that determine the velocity in
endurance events (13, 24, 26). Hence, an increased economy
following LHTL would likely have improved our subjects’
performance in the time-trial tests. However, we found no
indications for LHTL to affect whole-body VO2 during sub-
maximal cycling performed on numerous occasions. Although
an unchanged economy following LHTL has been reported
previously (39), it is difﬁcult to explain the difference with the
studies in which a reduced submaximal exercise VO2 has been
observed (19, 28, 29, 52, 53). Nevertheless, none of these
studies provides an objective description of training intensity,
which was either controlled by subjective feedback from the
athletes (19, 52) or not at all (28, 29, 53). It is therefore
appealing to speculate that the open-label treatment and a
concomitant placebo effect motivated LHTL subjects to train
harder than their control counterparts, which in turn, may have
improved running economy (15).
In summary, the present results provide no indication for
LHTL to enhance whole-body exercise economy to an extent
that improves aerobic performance. This is in line with our
primary ﬁnding that LHTL did not enhance any of the param-
eters that usually determine endurance performance.
Effect of LHTL on VO2max in Hypoxia
Winter sports, as well as disciplines from other sports,
regularly hold competitions at altitudes 2,500 m. Even the
mild hypoxia associated with such altitudes impairs VO2max
by reducing CaO2 (22, 43), and this appears to be pronounced
in highly trained individuals (30, 31). Athletes may attenuate
this undesirable effect by means that stimulate erythropoiesis
and thus normalize arterial blood O2 content. Accordingly,
preliminary acclimatization may partly restore VO2max in
moderate hypoxia (2, 9). Furthermore, the ergogenic effect of
erythropoietic stimulation by recombinant human Epo treat-
ment is pronounced when exercise is performed at moderate
altitude (47). Consequently, preliminary altitude exposure may
be crucial for the success in endurance races at altitude,
particularly on an elite level, where differences in the range of
0.5% may determine the outcome (21). However, during the
time span required for altitude acclimatization, athletes have to
acquiesce the detrimental impact of hypoxia on high-intensity
training quality (6), which may counteract a potential advan-
tage obtained by erythropoiesis. LHTL appears to be an elegant
approach to avoid this dilemma, since it may allow for altitude
acclimatization while training intensities can be maintained.
This was supported by a recent study, where 3 wk of LHTL
partially restored VO2max at an altitude of 2,340 m (55).
However, this study was designed without a placebo or even a
control group, and thus the contribution of a placebo effect
and/or training effect cannot be ruled out.
In contrast to these previous ﬁndings, the present data do not
support the hypothesis that LHTL partly normalizes VO2max
at the simulated altitude of 2,500 m. The observation that
VO2max in moderate hypoxia was unchanged after LHTL, in
spite of a signiﬁcant increase in [Hb], suggests that either
maximal cardiac output or O2 extraction or both were reduced
at that time. We conclude that for competitions at moderate
altitude, precedent LHTL does not provide an athletic advan-
tage, at least in elite cyclists.
Limitations
As discussed earlier, we observed a signiﬁcant hemoconcen-
tration in both groups, which may have suppressed Epo in the
LHTL group (4). Although an Epo response was suggested in
the urinal samples obtained from the LHTL group, it has to be
emphasized that urinal measurements provide neither the tem-
poral nor quantitative validity of blood measurements (38).
Accordingly, we can only draw limited conclusions regarding
the contribution of the hemoconcentration to our negative
ﬁndings.
Another potential limitation is related to the training pre-
scription for the LHTL group, as subjects were instructed to
maintain training as constant as possible. Although this has not
been scientiﬁcally conﬁrmed, a slight reduction of training
effort at the onset of a LHTL camp may be preferable in
practice to avoid overtraining. However, since we considered
the blinding of our subjects toward the group classiﬁcation
most relevant, we could not adapt the training prescriptions to
the (simulated) living altitude. Nevertheless, we are convinced
that this issue did not mask any effects of the intervention,
since in previous studies in which ergogenic effects of LHTL
were observed, training efforts were also equal between groups
(7, 34, 50). Furthermore, since our subjects were competing in
various disciplines and different countries, the present study
included both—athletes preparing for an upcoming season
(n  10) and others that had ﬁnished their season prior to the
study (n  6). To avoid potential bias from this issue, we
equally distributed the athletes of different disciplines, as well
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as pre- and postseason athletes, over both groups and clearly
instructed them to maintain training effort throughout the
study. Nevertheless, we cannot exclude a slight inﬂuence of
this issue on performance/motivation of our subjects, and the
resulting noise of our measurements may have covered small
effects of the intervention.
It should also be considered in this context whether the
training effort of our subjects was sufﬁcient to prevent detrain-
ing, which may also have masked an ergogenic impact in the
LHTL group. However, the positive development of time-trial
performance and VO2max in our already highly trained ath-
letes speaks against this.
It is important to note that our protocol did not allow
subjects to schedule a pronounced recovery period prior to
exercise tests, which is in contrast to preparation for an actual
competition. To avoid disturbance of the subjects’ training
regime, we instructed them to perform only one easy training
day prior to exercise tests, which is just a minimal form of
tapering and might have slightly hampered performance in the
tests. This was, however, the same for both groups, and it is
thus doubtful that differences between groups were masked by
fatigue.
Furthermore, it has to be considered whether the moderate
elevation of our living and testing facilities contributed to the
results of our study. However, a beneﬁcial impact of a eryth-
ropoietic response would, if at all, be more pronounced in mild
hypoxia (47). It may also be argued that the initial 2 wk at
1,135 m (the lead-in period) might have triggered a slight
physiological response that has hampered a further adaption in
the LHTL group during the intervention period. This is, how-
ever, unlikely, since even at the higher altitude of 1,600 m, no
effects on [Hb] or hematocrit are usually observed (60). Most
importantly, it must be acknowledged that in a previous LHTL
study conducted in the same facilities and with a very similar
protocol, the intervention improved the aerobic performance of
runners (7). Hence, the natural elevation of the housing/testing
facilities seems not to be a relevant factor for the outcome of
our study.
Finally, we chose to perform the LHTL study using normo-
baric hypoxia, and thus we can only draw limited conclusion
regarding LHTL at natural altitude. Future studies will have to
establish whether athletes respond differently to these two
forms of hypoxia.
Conclusion
Contrary to our hypothesis, the present results indicate that
LHTL, using normobaric hypoxia, may not improve endurance
performance at sea level or moderate altitude more than con-
ventional training. Our results further suggest that the erythro-
poietic response to LHTL is subject to considerable interindi-
vidual variation and may be blunted in elite athletes, where
baseline Hbmass/RCV is already high. Finally, it is indicated
that daily room conﬁnement in elite athletes may lead to a
reduction in plasma volume and thereby, counteract a potential
erythropoietic response to normobaric LHTL. Future studies
are encouraged to investigate the parameters underlying the
interindividual variation in the response to LHTL and to
compare the effects of LHTL at terrestrial altitude with those
obtained with normobaric hypoxia.
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ABSTRACT
It remains unclear by which mechanism ‘live high–train
low’ (LHTL) altitude training increases exercise
performance. Haematological and skeletal muscle
adaptations have both been proposed. To test the
hypotheses that (i) LHTL improves maximal oxygen
uptake (VO2max) and (ii) this improvement is related to
hypoxia-induced increases in total haemoglobin mass
(Hbmass) and not to improved maximal oxidative capacity
of skeletal muscle, we determined VO2max before LHTL
and after LHTL, before and after the altitude-induced
increases in Hbmass (measured by carbon-monoxide
rebreathing) had been abolished by isovolumic
haemodilution. We obtained skeletal muscle biopsies to
quantify mitochondrial oxidative capacity and efﬁciency.
Sixteen endurance-trained athletes were assigned
(double-blinded, placebo controlled) to ≥16 h/day over
4 weeks to normoxia (placebo, n=6) or normobaric
hypoxia equivalent to 3000 m altitude (LHTL, n=10).
Four-week LHTL did not increase VO2max, irrespective of
treatment (LHTL: 1.5%; placebo: 2.0%). Hbmass was
slightly increased (4.6%) in 5 (of 10) LHTL subjects but
this was not accompanied by a concurrent increase in
VO2max. In the subjects demonstrating an increase in
Hbmass, isovolumic haemodilution elicited a 5.8%
decrease in VO2max. Cycling efﬁciency was altered
neither with time nor by LHTL. Neither maximal capacity
of oxidative phosphorylation nor mitochondrial efﬁciency
was modiﬁed by time or LHTL. The present results
suggest that LHTL has no positive effect on VO2max in
endurance-trained athletes because (i) muscle maximal
oxidative capacity is not improved following LHTL and
(ii) erythrocyte volume expansion after LHTL, if any, is too
small to alter O2 transport.
INTRODUCTION
The concept of ‘live high–train low’ (LHTL) was
introduced to preserve the ability to train at a high
intensity while acclimatising to hypoxia1 and has
repeatedly demonstrated a positive effect on
VO2max and sea-level performance.2 3 Although the
ergogenic effect of LHTL has not been unequivo-
cally conﬁrmed, LHTL is nonetheless considered a
strategy to increase aerobic performance,4–6 even if
the potential improvement remains modest.7
Assuming that there is an effect of hypoxic expos-
ure on VO2max, the question arises which physio-
logical mechanism(s) might be involved. Two
hypoxia-related mechanisms were proposed, one
being ‘central’, that is, an altitude-induced increase
in total red blood cell volume (RCV)4 and the other
mechanism being an increase in skeletal muscle efﬁ-
ciency.5 The rationale for an increased RCV (or total
haemoglobin mass, Hbmass) to be the main mechan-
ism of LHTL is that (i) RCV is increased in propor-
tion to the residing altitude,8 (ii) when sufﬁcient
altitude ‘time’ is allowed, RCV is increased in most
athletes participating in LHTL studies,2 9–15 (iii)
augmentation of RCV with autologous blood trans-
fusion16 or recombinant erythropoietin17 18
increases aerobic performance and (iv) in those ath-
letes for whom RCV is increased in response to
LHTL, also VO2max is increased.19
However, it is argued that attributing performance
increases solely to enhanced erythropoiesis and RCV
is inadequate,5 since some LHTL studies have
observed only minor change in RCV whereas at the
same time running economy was improved,20–22 sug-
gesting increased muscular efﬁciency. Although the
underlying mechanism has not been demonstrated,
it may be that acclimatisation to altitude could
improve oxidative enzyme activity and/or mitochon-
drial function, as shown after a hypoxic training
intervention (live low–train high).23 The suggestion
of an effect of hypoxia on training-induced muscle
adaptation is, however, not supported by muscle
enzyme activity24 or exercise economy data.25
Our study aimed to test two hypotheses: (i) nor-
mobaric LHTL improves VO2max in endurance-
trained athletes, and (ii) improvement in VO2max
following LHTL is related to hypoxia-induced
increase in RCV (or Hbmass) and not to increased
maximal oxidative capacity of skeletal muscle. Our
previous report indicates not only that LHTL did
not improve VO2max in our group of 10 athletes
(hypothesis 1 was therefore not veriﬁed) but also
that Hbmass response to LHTL was variable, being
positive in only half of the LHTL subjects.26 The
present paper examines the role of increased
Hbmass on VO2max response to LHTL (hypothesis 2)
by means of isovolumic haemodilution and reports
on skeletal muscle mitochondrial function to gain
insight into the mechanisms that may be respon-
sible for the potential change in cycling efﬁciency.
METHODS
The present experiment is part of a double-blind,
placebo-controlled study on LHTL reported in
detail elsewhere.26
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Sixteen (15 males and 1 female) trained cyclists (n=13) and
triathletes (n=3), age 29±6 years (mean±SD), height 179±8 cm
and body weight 69±9 kg participated in the study after giving
oral and written informed consent. The study was approved by
the Ethics Committee of Zurich (2010-066/0) and Vaud (215/10)
(Switzerland), and conformed to the Declaration of Helsinki.
Study design
All subjects resided at the Centre National de Ski Nordique
(1135 m, Prémanon, France) while all experimental procedures
were performed at the neighbouring La Vallée hospital (1020 m,
Le Sentier, Switzerland).
During the ﬁrst 2 weeks (lead-in period) all subjects were
exposed to the normal environment at Prémanon. For the
following 4 weeks (intervention period), the subjects were
assigned in a double-blinded, placebo-controlled manner to
≥16 h/day of either normobaric normoxia (placebo group,
n=6) or normobaric hypoxia equivalent to 3000 m of altitude
(LHTL group, n=10). Two testing sessions were scheduled for
the present study, the ﬁrst one during the lead-in period (base-
line), and the second one during the last 3 days of the LHTL
intervention period (W4).
Training
Details of the training protocol and results are reported else-
where.26 The subjects followed their own training habits and
were instructed to keep the training intensity and load as stable
as possible during the 6 weeks. Training was evaluated daily
with a heart rate monitor, and in addition some of the subjects
recorded their training load with power metres.27 The average
exercise intensity spent (time/week) at a given exercise inten-
sity indicated equivalent training between groups. During
weeks W3 and W4, the subjects were asked to taper in prepar-
ation for the test sessions. No differences were observed across
time and study group with respect to exercise intensity,
whereas the quantiﬁed total training time decreased signiﬁ-
cantly with regard to time in both groups but with no differ-
ence between the two groups.
Experimental protocols
Incremental exercise to exhaustion was carried out on an elec-
tronically braked cycle-ergometer (Monark E-839, Varberg,
Sweden). The exercise protocol started with a warm-up period
of 5 min at a workload of 150 W followed by 5 min at 200 W
(100 and 150 W for the female athlete). Thereafter, the work-
load was increased by 25 W every minute until exhaustion.
Attainment of maximal oxygen uptake was established by
standard criteria.28 Expired gas were continuously measured
(Quark, Cosmed, Rome, Italy). Breath-by-breath values were
averaged over 30 s and the highest averaged value was termed
as VO2max. Each subject performed two maximal exercise tests
during the lead-in period. The largest VO2max result between
the two tests was used to express the baseline VO2max.
Hbmass was quantiﬁed by a modiﬁed version29 of a carbon
monoxide (CO)-rebreathing technique.30 A detailed description
of this procedure is given elsewhere.26 Hbmass was determined
twice during the lead-in period (baseline) and twice during the
fourth week of LHTL intervention (W4). Baseline and W4
values therefore correspond to the average of duplicate measure-
ment. The coefﬁcient of variation for Hbmass, assessed from
duplicate baseline during the lead-in period, and expressed
as the percent typical error (ie, SD of difference scores/√2),
was 2.6%.
Isovolumic haemodilution
To test the hypothesis that augmented RCV is the primary
mediator of enhanced VO2max following LHTL, maximal exer-
cise was performed before and after isovolumic haemodilution
at the end of the intervention period (W4). We withdrew the
amount of extra red blood cells that was gained after LHTL by
phlebotomy, and this volume was replaced by 6% hydroxyethyl
starch (Voluven 6%, Fresenius Kabi, Bad Homburg, Germany)
needed to achieve blood volume and RCV values similar to
those measured at baseline. For each subject, the volume of
blood to be withdrawn was calculated as ΔHbmass/[Hb]×100,
with ΔHbmass being the change in Hbmass with LHTL interven-
tion and [Hb], resting haemoglobin concentration at W4 (mea-
sured by a Radiometer ABL800 FLEX analyser). Taking into
account analytical variability for Hbmass determination, phle-
botomy was conducted only if the volume of blood to be
removed exceeded 190 ml. Within 15 min after completion of
the ﬁrst exercise bout, blood was withdrawn into a blood bag
(MRG6282L or MCG2272L, Macopharma, Mouvaux, France)
positioned on a mixing scale (Docon, Möller Medical, Fulda,
Germany), and then stored at 4°C. Hydroxyethyl starch infu-
sion was initiated immediately after phlebotomy. In subjects
for whom plasma volume decreased without a concomitant
change in Hbmass, only the starch infusion was performed. The
subjects were blinded towards the procedure by placing their
arm through a screen. In subjects for whom no manipulations
were necessary, blood was withdrawn and reinfused to simulate
these procedures. The second maximal test was initiated 2 h
after the end of the ﬁrst bout of exercise. After completion of
the second exercise test, the subjects were either reinfused with
their own blood, or infused with saline, again by using a
blinded design. Blood sampling and infusion were performed
via an 18-G catheter inserted in an arm vein.
Haematological measurements
Blood viscosity (in centipoises, cps) was measured within 3 h
after blood collection in EDTA tubes with a cone/plate viscom-
eter (Model DV-II, Brookﬁeld Engineering Laboratories,
Middleboro, Massachusetts, USA) with CPE40 spindle at three
shear rates (45, 90 and 225/s).
Skeletal muscle biopsy and preparation of muscle ﬁbres
Under local anaesthetics using the Bergström technique with
suction, skeletal muscle biopsies (∼20 mg) were obtained from
the vastus lateralis muscle at baseline and at W4. The biopsy
was dissected free of fat and connective tissue and thereafter
measured for mitochondrial respiration, as previously reported.31
Measurements of oxygen consumption were performed using
the high-resolution Oroboros Oxygraph-2k (Oroboros,
Innsbruck, Austria). Two substrate-uncoupler-inhibitor-titration
protocols were used in this study (i) to measure maximal cap-
acity of oxidative phosphorylation and (ii) to identify speciﬁc
ﬂux control ratios suggestive of mitochondrial efﬁciency or
coupling capacity (respiratory control ratio and leak control
coupling). Analysis of citrate synthase activity is also reported in
our previous report.31
Statistics
Nonparametric Mann-Whitney U-test was used to test the
effect of LHTL (versus placebo). Within a given group (placebo
or LHTL), the effect of time or isovolumic haemodilution
(baseline, W4, W4 after isovolumic haemodilution) on the
different parameters was evaluated with the use of Friedman
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non-parametric test and planned pair-wise-speciﬁc comparisons
were made using the Wilcoxon test. The same procedure was
also applied by considering three groups rather than two (ie,
placebo (n=6); LHTL(+) (n=5) and LHTL(−) (n=5)), LHTL(+)
and LHTL(−), respectively, referring to the subgroups of ‘respon-
ders’ and ‘non-responders’, that is, the athletes who did (or did
not) increase their Hbmass following 4 weeks of LHTL (W4).
Statistics were carried out with the Statview 5.0 software (SAS
Institute, Cary, North Carolina, USA). The values are reported
as arithmetic means±SD unless otherwise stated. Differences
were considered as signiﬁcant for p<0.05.
RESULTS
Four weeks of normobaric LHTL did not increase VO2max
LHTL resulted in a non-signiﬁcant increase in VO2max (relative
to body mass), being 1.5% in LHTL (n=10) and 2.0% in
placebo subjects (n=6) (table 1). Maximal workload was non-
signiﬁcantly augmented by 2.2% in LHTL and by 2.7% in
placebo subjects.26
LHTL induced an increase in Hbmass in 50% of the athletes
The increase in Hbmass among the 10 athletes exposed to LHTL
was marginal since ﬁve subjects did not increase Hbmass
(LHTL(−)), while the other ﬁve experienced a 4.6% increase in
Hbmass (LHTL(+)) (table 1 and ﬁgure 1). All subjects developed
haemoconcentration during the study.26 Blood viscosity was
similar between groups, and unchanged after LHTL or placebo
intervention (W4).
LHTL-induced gain in Hbmass is not associated with a
concurrent increase in VO2max
Maximal workload increased in LHTL(+) but not in LHTL(−),
suggesting a link between Hbmass and performance gain after
LHTL (table 1); however this was not supported by VO2max
data, indicating that LHTL(+) athletes experienced a non-
signiﬁcant 1.0% gain in VO2max after LHTL, comparable to
the also non-signiﬁcant 2.1% gain observed among LHTL(−)
athletes (table 1 and ﬁgure 1).
Suppression of the LHTL-induced gain in Hbmass resulted in a
signiﬁcant reduction of VO2max
LHTL(+) subjects presenting with Hbmass expansion and
plasma volume contraction after LHTL underwent blood with-
drawal (280±74 ml), followed by plasma expander infusion
(540±89 ml), while LHTL(−) and placebo subjects, presenting
with no change in Hbmass but plasma volume contraction,
received plasma expander only, respectively, 572±299 and 567
±169 ml. These interventions allowed for [Hb] to decrease, on
average (n=16), from 15.0±0.8 g/dl before isovolumic haemodi-
lution to 14.1±0.7 g/dl after isovolumic haemodilution, that is,
at a level comparable to baseline value (14.0±0.5 g/dl).
Isovolumic haemodilution decreased VO2max in LHTL(+),
while plasma expander infusion per se had no effect on
VO2max in LHTL(−) (table 1 and ﬁgure 1). Maximal workload
was reduced in LHTL(+) but not in LHTL(−). Plasma expander
infusion did not signiﬁcantly alter maximal workload in
placebo athletes but did decrease their VO2max signiﬁcantly.
Cycling efﬁciency was not altered following LHTL
Cycling efﬁciency at 150 and 200 Wremained unchanged through-
out the study, in both the placebo and LHTL groups.26 Isovolumic
haemodilution did not alter cycling efﬁciency (table 1).
LHTL was not associated with changes in mitochondrial
content or function
Mitochondrial content (ie, citrate synthase activity) was
altered neither by LHTL nor by time (ﬁgure 2A). Mitochondrial
function (oxygen ﬂux per unit of mitochondrial content) was
similar in both groups, both at baseline and at W4 (ﬁgure 2B).
The respiratory control ratio and leak control coupling, both
indicative of mitochondrial efﬁciency, were found similar
Table 1 Submaximal exercise, maximal exercise and total haemoglobin mass
Placebo (n=6) LHTL(+) (n=5) LHTL(−) (n=5)
Baseline W4 Baseline W4 Baseline W4
Submaximal O2 uptake
VO2 at 150 W (l/min) 2472±288 2447±170 2438±160 2351±83 2409±147 2366±186
Isovolumic haemodilution – 2396±212 – 2392±167 – 2332±218
VO2 at 200 W (l/min) 3007±212† 3015±148† 3043±158 2957±177 3097±106 3005±91
Isovolumic haemodilution – 2998±313 – 2937±165 – 3022±138
Maximal O2 uptake and workload
VO2max (ml/min) 4948±446† 5050±485† 4924±582 4958±650 4557±726 4521±676
Isovolumic haemodilution – 4797±504 – 4672±583 – 4536±722
VO2max (ml/min/kg) 70.8±5.3 72.3±6.0 73.5±2.9 74.3±4.8 65.1±4.8 66.5±5.5
Isovolumic haemodilution – 68.6±5.2** – 70.0±4.0** – 66.6±4.6
Maximal workload (W) 411±23† 422±28† 412±50 432±49* 398±72 394±62
Isovolumic haemodilution – 412±29 – 406±48** – 386±61
Total haemoglobin mass
Hbmass (g) 984±98† 971±80† 928±92 970±93* 933±219 908±225
Hbmass (g/kg) 14.06±0.76 13.88±0.60 13.87±0.97 14.58±0.95* 13.14±1.00 13.12±1.15
Values are means±SD. Within the live high–train low (LHTL) group of 10 athletes, LHTL(+) and LHTL(−), respectively, refer to the subgroups of ‘responders’ and ‘non-responders’,
that is, the athletes who did (or did not) increase their total haemoglobin mass (Hbmass) following 4 weeks of LHTL (W4). Isovolumic haemodilution was performed at W4, after
the first incremental test had been completed. LHTL(+) subjects were isovolumically haemodiluted by means of phlebotomy and plasma volume expander (PVX) infusion,
whereas LHTL(−) and placebo subjects received PVX infusion only. Hbmass, total haemoglobin mass (absolute and adjusted to body weight); VO2max, maximal O2 uptake
(absolute and adjusted to body weight); maximal workload (Wmax) was calculated as: Wmax=Wcompl+25×(t/60), where Wcompl is the last workload completed, t is seconds
that the final, not completed workload was sustained and 25 (W) is the increment in workload. For VO2 at 200 W, n=4 for LHTL
(−).
*p<0.05 vs baseline, **p<0.05 vs W4.
†These data are reproduced from our previous report26 for the sake of clarity.
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between groups at baseline and unchanged following LHTL or
placebo intervention (ﬁgure 2C,D).
DISCUSSION
Using a double-blinded, placebo-controlled design we found
that LHTL induced no positive effect on VO2max in endurance
athletes. Only 5 of 10 LHTL athletes responded by increasing
Hbmass. These ‘responders’ also increased maximal workload
but not VO2max in comparison with either their non-
responding LHTL counterparts or the placebo athletes. The
importance of Hbmass and/or [Hb] for O2 transport during
maximal exercise was however conﬁrmed since isovolumic
haemodilution resulted in a decrease in both VO2max and
maximal workload. Finally, LHTL did not affect skeletal muscle
mitochondrial function or whole body cycling efﬁciency.
Response of Hbmass to LHTL and its role on VO2max
Data analysis revealed that 5 of 10 LHTL subjects did increase
Hbmass, suggesting a signiﬁcant variability among athletes with
regard to the haematological response to hypoxia, and that
moderate hypoxia may provide, at least in some athletes, a suf-
ﬁcient stimulus for red blood cell synthesis to be increased.
Similarly, Chapman et al19 found that only 53% (17 of 32 sub-
jects) exhibited an expansion of RCV in response to altitude
training. The different Hbmass response among our LHTL sub-
jects was not explained by the degree of haemoconcentration or
by the increase of reticulocyte count. Also an increase in
Hbmass following LHTL was not accompanied by a concomi-
tant rise in VO2max, conﬁrming previous data,9 which ques-
tions the signiﬁcance of the small Hbmass improvements
detected in athletes undergoing the LHTL regimen. Of note,
after blood transfusion, only 50% of the added O2 delivery may
be utilised by the tissues.32 Nevertheless, it could be that
highly trained individuals require a larger increase in Hbmass to
increase VO2max as normal healthy individuals.
In spite of their ‘insensitivity ’ to slightly increased O2 deliv-
ery, the LHTL athletes were critically dependent on convective
O2 transport, since acute normalisation of Hbmass via isovolumic
haemodilution provoked a signiﬁcant drop in maximal power
output and VO2max. Similarly, lowering of Hbmass through
Figure 1 The effects of live high–train low (LHTL) and isovolumic haemodilution on haemoglobin mass (Hbmass) and VO2max. The upper panels
show the individual response of total Hbmass (in absolute values), induced by 4 weeks of placebo (n=6) or live high—train low intervention (LHTL;
n=10). LHTL athletes were divided, according to their individual changes in Hbmass, into ‘responders’ (LHTL
(+), n=5) or ‘non-responders’ (LHTL(−),
n=5). Of note is that intervention was associated with a decrease in plasma volume in all subjects.26 The lower panels show ﬁrst the concurrent
individual changes in VO2max (in absolute values), in response to LHTL or placebo intervention (W4 vs baseline), and second the modulation of
these changes in response to acute isovolumic haemodilution, aimed at restoring intravascular volumes to basal values. The subjects who gained
Hbmass after intervention (ie, LHTL
(+)) were isovolumically haemodiluted by means of phlebotomy and plasma volume expander (PVX) infusion,
whereas those who did not increase their Hbmass (ie, LHTL
(−) and placebo) received PVX infusion only. Histograms indicate means. *p<0.05 vs
baseline; **p<0.05 vs W4.
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blood donation33 or haemodilution16 decreases VO2max. On the
contrary, the effect of clamping Hbmass during LHTL (via
repeated phlebotomy) on maximal aerobic performance was
found to be marginal,10 but such procedure substantially differs
from acute isovolumic haemodilution.
An important factor to consider during blood withdrawal
and/or haemodilution (secondary to plasma expander infusion)
is the acute reduction in [Hb], which is known to decrease
VO2max, because of a reduction of the oxygen-carrying cap-
acity of blood.34 Although not in line with previous data in ath-
letes indicating no change in VO2max following plasma volume
expansion,35 our ﬁnding demonstrating that VO2max decreased
after haemodilution in the placebo group conﬁrms the import-
ant role of [Hb] on VO2max, further suggesting that Hbmass
per se is not the only factor controlling VO2max after isovolu-
mic haemodilution in the LHTL(+) group. Conversely, the
ﬁnding that haemodilution did not affect VO2max in the
LHTL(−) group suggests only a minor contribution of [Hb].
Whatever the exact role of [Hb] on VO2max, our data imply
that LHTL(−) athletes, unlike placebo subjects, compensated for
reduced arterial O2 content by achieving higher maximal
cardiac output and/or O2 extraction. Although stroke volume
was not measured in the present study, we speculate that
cardiac response after isovolumic haemodilution was not much
different between placebo and LHTL subjects since (i) infused
volume was identical and (ii) decreases in maximal heart rate
were small (3–4 beats/min) and similar between groups.
We cannot exclude that incomplete recovery after the ﬁrst
VO2max test may have contributed to some fatigue during the
second exercise bout. However, VO2max should have recovered
within 2 h36 37 and athletes are accustomed to perform repeated
bouts of high-intensity exercise.
Mitochondrial function is not improved following LHTL
Hypoxic regulation of mitochondrial expression is not well
understood. Skeletal muscle mitochondrial volume density,38
enzyme activities39 and protein content40 have all been
observed to decrease following extended hypoxic exposure
while other studies have shown negligible differences in
mitochondrial-speciﬁc biochemical expression.41–44 We have pre-
viously found no signiﬁcant alteration in respiratory chain
function in lowland natives measured at sea level and again fol-
lowing 7–9 days of high-altitude exposure,45 and the ﬁndings in
the current study support these data as mitochondrial function
in the LHTL subjects did not differ from data obtained in the
control subjects. The present observation at the tissue level pro-
vides a basis for explaining why cycling efﬁciency remained
unchanged following LHTL. Other explanations may be related
to unchanged motor control and/or biomechanics, which are
also determinants of exercise efﬁciency.46
CONCLUSION
In the present study VO2max did not increase in response to
LHTL and potential mechanisms that could inﬂuence VO2max
were not identiﬁed: we evaluated both central and peripheral
adaptations to LHTL and found no effect in highly trained
individuals. Furthermore, even though LHTL caused modest
erythrocyte volume expansion in some individuals, these
Figure 2 Live high–train low (LHTL) does not alter mitochondrial function of skeletal muscle. The ﬁgure shows the mitochondrial function of skeletal
muscle in subjects assigned to the placebo (n=6) and LHTL (n=9) groups. Open bars represent baseline measurements and grey bars represent
measurements following 4 weeks of respective treatment (W4). Panel A shows citrate synthase activity. Panel B shows maximal oxidative
phosphorylation capacity, expressed per unit of citrate synthase activity. Panel C shows respiratory control ratio, presented as the ratio of maximal
state 3 respiration through complex I to malate-induced (2 mM) and pyruvate-induced (5 mM) leak respiration. Panel D shows leak coupling control
presented as the ratio of malate-induced (2 mM) and pyruvate-induced (5 mM) leak respiration to maximal state 3 respiration through complex I (PI).
Values are reported as mean±SE.
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subjects did not enhance their VO2max. In conclusion, the
positive effects of LHTL on O2 transport appear to be negligible
among elite cyclists who already possess very high aerobic cap-
acities conferred by high Hbmass and VO2max.
What this study adds
▸ This study provides a mechanistic basis to explain why
normobaric live high–train low (LHTL) does not boost
VO2max in endurance-trained athletes:
– The modest increase in haemoglobin mass conferred by
LHTL is not sufﬁcient to further increase the athlete’s
high VO2max, even if VO2max critically depends on
Hbmass in this population.
– Unchanged maximal oxidative capacity or mitochondrial
efﬁciency after LHTL provides evidence against the
hypothesis that LHTL may improve muscle efﬁciency and
therefore VO2max.
▸ Extrapolation to natural altitude is limited since hypobaric
hypoxia could induce different responses than those
occurring with normobaric hypoxia,47 48 although this
seems unlikely to have major implications in the present
setting.
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3. Discussion and outlook 
The aim of this project was to enhance our understanding of the interaction between hypoxia 
and aerobic exercise. Specifically, we tested whether the HPV-induced rise in PAP and the 
decline in cerebral oxygenation contribute to the limited exercise capacity in acute hypoxia. 
Furthermore, we examined the effect of LHTL altitude training on the performance of elite 
athletes and evaluated underlying physiological mechanisms. As the results obtained in each 
study are discussed in detail in the corresponding articles, this section summarizes the key 
points and highlights future directions for research within the fields. 
 
3.1 Limitations to exercise in acute hypoxia induced by the pulmonary circulation 
The reduced VO2max in acute hypoxia is mainly related to an attenuated skeletal muscle O2 
supply, which is induced by the detrimental effect of hypoxia on caO2 and, in severe hypoxia, 
maximal cardiac output (25, 125). It is notable that these mechanisms also constitute the main 
reasons for exercise intolerance in pulmonary hypertension patients (89, 90, 124). As the HPV 
transiently induces pulmonary hypertension (87) this may thus contribute to the factors that 
limit VO2max in hypoxia. We tested this hypothesis in HAPE-susceptible individuals as they 
experience an excessive HPV and are thus convenient subjects for this purpose. 
In agreement with an earlier study (40) our results indicate that pharmacological attenuation 
of PAP partially restores hypoxic VO2max in HAPE-susceptible subjects without affecting 
SaO2 during maximal exercise (114). Subsequently, the direct comparison between normal 
and HAPE-susceptible subjects revealed a higher PAP during exercise in hypoxia and a 
tendency for a more pronounced decrease in VO2max in the latter but no differences in SaO2 
at exhaustion (115). Taken together these findings support the concept of PAP as a limiting 
factor for exercise in hypoxia and favour right ventricular restriction rather than an impaired 
pulmonary O2 diffusion as perpetrator. This mechanism might at least partly underlie the 
largely unexplained reduction in maximal cardiac output that contributes to the decline in 
VO2max at altitudes > 4,500 m (25). Nevertheless, as it was the case in previous studies (38-
40, 88, 97) we could not include measurements of maximal cardiac output and direct evidence 
for this hypothesis thus remains to be provided. 
Accordingly, the aim of our next study within this area is a direct assessment of the impact of 
PAP on the reduction in maximal cardiac output in severe hypoxia. The key intervention will 
be the catheterization of the pulmonary artery which allows for reliable measurement of PAP 
and cardiac output also during maximal exercise (120, 130). Shortly before exhaustion acute 
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specific pulmonary vasodilation will be induced by inspiratory nitric oxide (NO) 
administration (43) and the resulting effect on maximal cardiac output and VO2max will be 
determined. 
 
3.2 Limitations to exercise in acute hypoxia induced by the cerebral circulation 
Hypoxia promotes the development of central fatigue by increasing the discharge frequency 
of inhibitory muscle afferents (60, 72). Furthermore, observations during acute re-
oxygenation have led to speculations that hypoxia may accelerate the onset of central fatigue 
by attenuation of cerebral oxygenation (8, 10). 
The second aim of this project was to provide direct evidence for this mechanism. By means 
of inspiratory CO2 supplementation we restored oxygenation specifically in the brain while 
the remaining organism was kept hypoxic (117). However, contrary to our hypothesis, and in 
line with the previous observations in more severe hypoxia (123), this did not increase 
VO2max and thus argues against cerebral hypoxia as a limiting factor for maximal exercise in 
acute hypoxia. Nevertheless, this does not rule out a limiting role in other types of exercise, as 
the incremental VO2max test induces a progressive demand for muscular O2 supply which 
may overcharge the cardiovascular system and lead to exhaustion before cerebral hypoxia 
becomes critical (17, 68, 109, 110). Future studies could thus examine whether inspiratory 
CO2 administration benefits performance in submaximal exercise tests in hypoxia. In addition, 
simultaneous infusion of bicarbonate may be applied to prevent the CO2 administration from 
accelerating the development of fatiguing acidosis (108) which may have biased the results of 
present and past work (123). 
 
3.3 The effect of Live High-Train Low on the exercise capacity of elite athletes 
Numerous studies in the past have indicated that acclimatization to hypoxia partially restores 
aerobic exercise capacity (62, 82, 113). As the underlying physiological adaptations may also 
improve performance in normoxia the use of preliminary hypoxic exposure has become a 
popular measure in the preparation for sea level events (76). Over the last four decades 
different altitude training strategies have been developed (111) among which LHTL appears 
to be the most promising (69). Nevertheless, there is disagreement regarding the efficiency of 
this training form, and the mechanisms underlying potential performance gains, as divergent 
results have been reported (112). Furthermore, the relevance of most positive findings are 
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limited by suboptimal study designs and the inclusion of inappropriate subjects (76). The last 
aim of this project was thus to test the effects of LHTL on elite athletes in a double-blinded 
and placebo-controlled trial and to determine the mechanisms underlying potential 
performance gains. 
Contrary to our hypothesis, the conducted study revealed that despite extensive hypoxic 
exposure no haematological (116) or skeletal muscle adaptations (102) were induced and, as a 
result, both VO2max and time trial performance remained unaffected by LHTL. Besides 
nourishing the speculations that previous findings may have been related to a placebo-effect 
(117) this led us to the conclusion that either a high baseline RCV made the elite athletes 
insensitive to the natural rise in circulating erythropoietin (76) or that four weeks of 
discontinuous exposure to moderate hypoxia are simply insufficient to stimulate 
erythropoiesis. 
In the near future we plan to conduct studies that clarify this issue. In a first attempt we aim to 
assess whether a four week sojourn at the Jungfraujoch research station (3,454 m) stimulates 
erythropoiesis in normally trained individuals. If an increase in RCV will be observed under 
these conditions the next step will be to conduct another LHTL study including both, elite 
athletes and normal subjects and compare the responses of these two populations. In contrast, 
if even a continuous residence at an altitude above that normally applied in LHTL will fail to 
stimulate erythropoiesis in non-athletes we will discard the commonly used LHTL strategy as 
a useful training tool. In this case it might be an option to assess whether an ergogenic 
adaptation may be induced if the degree of hypoxia is increased above the conventionally 
applied as it was hypothesized previously (100). Athletes have traditionally refrained from 
such a modification as they feared negative consequences for recovery or immunofunction 
(129). However, to date, this lacks solid evidence and could thus be another issue to clarify in 
a future LHTL study applying more severe hypoxia. 
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